Colgate-Palmolive (CL) 10-K 13 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Jan. 31, 2025	Jun. 30, 2024
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-644
Entity Registrant Name	COLGATE-PALMOLIVE COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-1815595
Entity Address, Address Line One	300 Park Avenue
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	212
Local Phone Number	310-2000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 79.2
Entity Common Stock, Shares Outstanding		811,536,437
Documents Incorporated by Reference	Documents Form 10-K Reference Portions of Proxy Statement for the 2025 Annual Meeting of Stockholders Part III, Items 10 through 14
Entity Central Index Key	0000021665
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	CL
Security Exchange Name	NYSE
0.500% Notes due 2026
Entity Information [Line Items]
Title of 12(b) Security	0.500% Notes due 2026
Trading Symbol	CL26
Security Exchange Name	NYSE
0.300% Notes due 2029
Entity Information [Line Items]
Title of 12(b) Security	0.300% Notes due 2029
Trading Symbol	CL29
Security Exchange Name	NYSE
1.375% Notes due 2034
Entity Information [Line Items]
Title of 12(b) Security	1.375% Notes due 2034
Trading Symbol	CL34
Security Exchange Name	NYSE
0.875% Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	0.875% Notes due 2039
Trading Symbol	CL39
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	New York, New York
Auditor Firm ID	238

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net sales	$ 20,101	$ 19,457	$ 17,967
Cost of sales	7,940	8,131	7,719
Gross profit	12,161	11,326	10,248
Selling, general and administrative expenses	7,729	7,151	6,565
Other (income) expense, net	164	191	69
Goodwill and intangible assets impairment charges	0	0	721
Operating profit	4,268	3,984	2,893
Non-service related postretirement costs	87	360	80
Interest expense	292	287	167
Interest income	67	55	14
Income before income taxes	3,956	3,392	2,660
Provision for income taxes	907	937	693
Net income including noncontrolling interests	3,049	2,455	1,967
Less: Net income attributable to noncontrolling interests	160	155	182
Net income attributable to Colgate-Palmolive Company	$ 2,889	$ 2,300	$ 1,785
Earnings per common share, basic (in dollars per share)	$ 3.53	$ 2.78	$ 2.13
Earnings per common share, diluted (in dollars per share)	$ 3.51	$ 2.77	$ 2.13

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income including noncontrolling interests	$ 3,049	$ 2,455	$ 1,967
Other comprehensive income (loss), net of tax:
Cumulative translation adjustments	(343)	98	(146)
Retirement plan and other retiree benefit adjustments	43	(16)	413
Gains (losses) on cash flow hedges	8	(7)	60
Total Other comprehensive income (loss), net of tax	(292)	75	327
Total Comprehensive income including noncontrolling interests	2,757	2,530	2,294
Less: Net income attributable to noncontrolling interests	160	155	182
Less: Cumulative translation adjustments attributable to noncontrolling interests	(8)	(42)	(4)
Total Comprehensive income attributable to noncontrolling interests	152	113	178
Total Comprehensive income attributable to Colgate-Palmolive Company	$ 2,605	$ 2,417	$ 2,116

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,096	$ 966
Receivables (net of allowances of $85 and $80, respectively)	1,521	1,586
Inventories	1,987	1,934
Other current assets	713	793
Total current assets	5,317	5,279
Property, plant and equipment, net	4,422	4,582
Goodwill	3,272	3,410
Other intangible assets, net	1,756	1,887
Deferred income taxes	195	214
Other assets	1,084	1,021
Total assets	16,046	16,393
Current Liabilities
Debt payable within one-year	660	330
Accounts payable	1,805	1,698
Accrued income taxes	403	336
Other accruals	2,891	2,377
Total current liabilities	5,759	4,741
Long-term debt	7,289	8,219
Deferred income taxes	343	361
Other liabilities	2,111	2,115
Total liabilities	15,502	15,436
Commitments and contingent liabilities	0	0
Shareholders’ Equity
Common stock, $1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued)	1,466	1,466
Additional paid-in capital	4,181	3,808
Retained earnings	26,145	25,289
Accumulated other comprehensive income (loss)	(4,222)	(3,937)
Treasury stock, at cost	(27,358)	(26,017)
Total Colgate-Palmolive Company shareholders’ equity	212	609
Noncontrolling interests	332	348
Total equity	544	957
Total liabilities and equity	$ 16,046	$ 16,393

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current Assets
Allowance for doubtful accounts receivable, current	$ 85	$ 80
Shareholders’ Equity
Common stock par value (in dollars per share)	$ 1	$ 1
Common stock authorized (in shares)	2,000,000,000	2,000,000,000
Common stock issued (in shares)	1,465,706,360	1,465,706,360
Debt payable within one year	$ 652	$ 20

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Millions		Total	Common Stock	Additional Paid-In Capital	Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Beginning balance at Dec. 31, 2021			$ 1,466	$ 3,269	$ (1)	$ (24,089)	$ 24,350	$ (4,386)	$ 362
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		$ 1,967					1,785		182
Other comprehensive income (loss), net of tax		327						331	(4)
Dividends	[1]						(1,562)		(135)
Stock-based compensation expense				125					0
Shares issued for stock options				190		226
Shares issued for restricted stock awards				(40)		40
Treasury stock acquired						(1,308)
Other				2		3
Ending balance at Dec. 31, 2022			1,466	3,546	(1)	(25,128)	24,573	(4,055)	405
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		2,455					2,300		155
Other comprehensive income (loss), net of tax		75						117	(42)
Dividends	[1]						(1,584)		(170)
Stock-based compensation expense				122
Shares issued for stock options				170		212
Shares issued for restricted stock awards				(34)		34
Treasury stock acquired						(1,128)
Other				4	1	(7)		1
Ending balance at Dec. 31, 2023		957	1,466	3,808	0	(26,017)	25,289	(3,937)	348
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		3,049					2,889		160
Other comprehensive income (loss), net of tax		(292)						(284)	(8)
Dividends	[1]						(2,034)		(168)
Stock-based compensation expense				135
Shares issued for stock options				284		354
Shares issued for restricted stock awards				(52)		52
Treasury stock acquired						(1,739)
Other				6		(8)	1	(1)
Ending balance at Dec. 31, 2024		$ 544	$ 1,466	$ 4,181	$ 0	$ (27,358)	$ 26,145	$ (4,222)	$ 332
[1] * Five dividends were declared in 2024. Four dividends were declared in 2023 and 2022.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2024 dividend $ / shares	Dec. 31, 2023 dividend $ / shares		Dec. 31, 2022 dividend $ / shares
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share) | $ / shares	$ 2.48	$ 1.91	[1]	$ 1.86	[1]
Number of dividends declared per quarter | dividend	5	4		4
[1] * Five dividends were declared in 2024. Four dividends were declared in 2023 and 2022.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Activities
Net income including noncontrolling interests	$ 3,049	$ 2,455	$ 1,967
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations:
Depreciation and amortization	605	567	545
ERISA litigation matter	0	267	0
Restructuring and termination benefits, net of cash	51	(23)	49
Stock-based compensation expense	135	122	125
Gain on the sale of land	0	0	(47)
Goodwill and intangible assets impairment charges	0	0	721
Deferred income taxes	(77)	(98)	(78)
Cash effects of changes in:
Receivables	(56)	(37)	(227)
Inventories	(100)	194	(333)
Accounts payable and other accruals	516	309	(115)
Other non-current assets and liabilities	(16)	(11)	(51)
Net cash provided by operations	4,107	3,745	2,556
Investing Activities
Capital expenditures	(561)	(705)	(696)
Purchases of marketable securities and investments	(574)	(506)	(470)
Proceeds from sale of marketable securities and investments	564	502	322
Payment for acquisitions, net of cash acquired	0	0	(809)
Proceeds from the sale of land	0	0	47
Other investing activities	37	(33)	5
Net cash used in investing activities	(534)	(742)	(1,601)
Financing Activities
Short-term borrowing (repayment) less than 90 days, net	93	(906)	540
Principal payments on debt	(503)	(903)	(406)
Proceeds from issuance of debt	2	1,495	1,513
Dividends paid	(1,789)	(1,749)	(1,691)
Purchases of treasury shares	(1,739)	(1,128)	(1,308)
Proceeds from exercise of stock options	638	380	418
Other financing activities	(91)	18	(18)
Net cash used in financing activities	(3,389)	(2,793)	(952)
Effect of exchange rate changes on Cash and cash equivalents	(54)	(19)	(60)
Net increase (decrease) in Cash and cash equivalents	130	191	(57)
Cash and cash equivalents at beginning of year	966	775	832
Cash and cash equivalents at end of year	1,096	966	775
Supplemental Cash Flow Information
Income taxes paid	933	937	945
Interest paid	$ 302	$ 280	$ 151

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations The Company manufactures and markets a wide variety of products in the U.S. and around the world in two product segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners and other similar items. These products are sold primarily to a variety of retailers, wholesalers, distributors, dentists and, in some geographies, skin health professionals. Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill’s Pet Nutrition. The principal customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and eCommerce retailers. Some of our products are also sold direct-to-consumer. Principal global and regional trademarks include Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. The Company’s principal classes of products accounted for the following percentages of worldwide Net sales for the past three years: 2024 2023 2022 Oral Care 43 % 42 % 43 % Personal Care 18 % 19 % 19 % Home Care 17 % 17 % 17 % Pet Nutrition 22 % 22 % 21 % Total 100 % 100 % 100 %

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned or controlled subsidiaries. Intercompany transactions and balances have been eliminated. The Company’s investments in consumer products companies with interests ranging between 20% and 50%, where the Company has significant influence over the investee, are accounted for using the equity method. Net income (loss) from such investments is recorded in Other (income) expense, net in the Consolidated Statements of Income. As of December 31, 2024 and 2023, equity method investments included in Other assets in the Consolidated Balance Sheets were $81 and $83, respectively. Unrelated third parties hold the remaining ownership interests in these investments. Investments with less than a 20% interest are recorded at cost and periodically adjusted based on observable price changes or quoted market prices in active markets, if applicable. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company’s assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates. Revenue Recognition The Company’s revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to “direct the use of” and “obtain the benefit from” our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company’s right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers. Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company’s historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company’s promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates. Sales returns are generally accepted at the Company’s discretion and are not material to the Company’s Consolidated Financial Statements. The Company’s contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses. Shipping and Handling Costs Shipping and handling costs (also referred to as logistics costs) are classified as Selling, general and administrative expenses and were $1,777, $1,771 and $1,874 for the years ended December 31, 2024, 2023 and 2022, respectively. Marketing Costs The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Inventories The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of the remaining inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current “Other assets.” Property, Plant and Equipment Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over the estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses. Goodwill and Other Intangibles Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis. Determining the fair value of the Company’s reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management’s strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations. As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information. Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit. Income Taxes The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes. Financial Instruments Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations. Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton ( “ Black-Scholes ” ) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans. Currency Translation The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year. For subsidiaries operating in highly inflationary environments, local currency-denominated non-monetary assets, including inventories, goodwill and property, plant and equipment, are remeasured at their historical exchange rates, while local currency-denominated monetary assets and liabilities are remeasured at year-end exchange rates. Remeasurement adjustments for these operations are included in Net income attributable to Colgate-Palmolive Company. Recent Accounting Pronouncements and Disclosure Rules In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2024-04, “Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.” This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants’ registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-08, “Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets.” This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information. In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In August 2023, the FASB issued ASU No. 2023-05, “Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement.” This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In March 2023, the FASB issued ASU No. 2023-01, “Leases (Topic 842): Common Control Arrangements.” This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company’s Consolidated Financial Statements. In September 2022, the FASB issued ASU No. 2022-04, “Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs’ key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated roll-forward information. The Company adopted the guidance beginning on January 1, 2023, and with respect to the roll-forward information disclosure, beginning on January 1, 2024. See Note 15, Supplier Finance Programs for additional information. Reclassifications

Restructuring and Related Imple

Restructuring and Related Implementation Charges	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Implementation Charges	Restructuring and Related Implementation Charges On January 27, 2022, the Board approved a targeted productivity program (the “2022 Global Productivity Initiative”). All initiatives have been implemented and the program concluded on December 31, 2024. The 2022 Global Productivity Initiative resulted in the reallocation of resources towards the Company’s strategic priorities and faster growth businesses, efficiencies in the Company’s operations and the streamlining of its supply chain to reduce structural costs. Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of $228 ($186 aftertax) in connection with the implementation of various projects as follows: Total Program Charges as of December 31, 2024 Employee-Related Costs $ 175 Incremental Depreciation 13 Asset Impairments 1 Other 39 Total $ 228 Total pretax charges resulting from the 2022 Global Productivity Initiative were comprised of the following categories: employee-related costs, including severance, pension and other termination benefits (80%); asset-related costs, primarily accelerated depreciation and asset write-downs (5%); and other charges (15%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. Over the course of the 2022 Global Productivity Initiative, approximately 80% of the charges resulted in cash expenditures. For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows: Twelve Months Ended December 31, 2024 2023 Gross Profit $ 20 $ 1 Selling, general and administrative expenses 6 2 Other (income) expense, net 59 24 Non-service related postretirement costs — 5 Total 2022 Global Productivity Initiative charges, pretax $ 85 $ 32 Total 2022 Global Productivity Initiative charges, aftertax $ 73 $ 25 Restructuring and related implementation charges are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance. Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments: Twelve Months Ended December 31, Total Program Charges 2024 2023 North America (1) 3 % 15 % 9 % Latin America — % — % 9 % Europe (1) 89 % 19 % 44 % Asia Pacific — % 20 % 7 % Africa/Eurasia — % 5 % 6 % Hill's Pet Nutrition 6 % 23 % 11 % Corporate 2 % 18 % 14 % Total 100 % 100 % 100 % (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13, Segment Information for additional details. The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals: Twelve Months Ended December 31, Employee-Related Incremental Asset Other Total Balance at December 31, 2022 $ 30 $ — $ 1 $ 3 $ 34 Charges 24 — — 8 32 Cash Payments (45) — — (10) (55) Charges against assets (5) — (1) — (6) Foreign exchange 6 — — — 6 Balance at December 31, 2023 $ 10 $ — $ — $ 1 $ 11 Charges 49 13 — 23 85 Cash Payments (20) — — (14) (34) Charges against assets — (13) — — (13) Foreign exchange (5) — — — (5) Balance at December 31, 2024 $ 34 $ — $ — $ 10 $ 44 Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements which are reflected as Charges against assets within Employee-Related Costs in the preceding table, as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities. Incremental Depreciation is recorded to reflect changes in useful lives and estimated residual values for long-lived assets that will be taken out of service prior to the end of their normal service period. Asset Impairments are recorded to write down inventories and assets held for sale or disposal to their fair value based on amounts expected to be realized. Charges against assets within Asset Impairments are net of cash proceeds pertaining to the sale of certain assets, as applicable.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in net carrying value of Goodwill by segment for the years ended December 31, 2024 and 2023 were as follows: 2023 Beginning Balance Foreign currency translation Ending Balance Oral, Personal and Home Care North America $ 906 $ 2 $ 908 Latin America 168 11 179 Europe 1,504 67 1,571 Asia Pacific 179 — 179 Africa/Eurasia 107 (19) 88 Total Oral, Personal and Home Care 2,864 61 2,925 Pet Nutrition 488 (3) 485 Total Goodwill $ 3,352 $ 58 $ 3,410 2024 Beginning Balance Reallocation (1) Foreign currency translation Ending Balance Oral, Personal and Home Care North America $ 908 $ 223 $ (23) $ 1,108 Latin America 179 — (34) 145 Europe 1,571 (223) (67) 1,281 Asia Pacific 179 — (1) 178 Africa/Eurasia 88 — (10) 78 Total Oral, Personal and Home Care 2,925 — (135) 2,790 Pet Nutrition 485 — (3) 482 Total Goodwill $ 3,410 $ — $ (138) $ 3,272 (1) As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reallocation of the goodwill, the Company completed an assessment indicating no goodwill impairment was required as a result of this segment reporting structure realignment. Refer to Note 13, Segment Information for additional information. Other intangible assets as of December 31, 2024 and 2023 were comprised of the following: 2024 2023 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trademarks - finite life $ 1,135 $ (545) $ 590 $ 1,167 $ (519) $ 648 Other finite life intangible assets 603 (385) 218 624 (363) 261 Indefinite life intangible assets 948 — 948 978 — 978 Total Other intangible assets $ 2,686 $ (930) $ 1,756 $ 2,769 $ (882) $ 1,887 The change in the net carrying amounts of Other intangible assets during 2024 was due to foreign currency translation and amortization expense of $75. Annual estimated amortization expense for each of the next five years is expected to be approximately $68. In 2023, the Company re-characterized a certain trademark from an indefinite to a finite life intangible asset based on an assessment of certain macroeconomic conditions, historical performance and demand. The carrying value of this trademark as of December 31, 2024 is $234 and is being amortized over its estimated remaining useful life of 24 years. As of the date of the annual impairment test of indefinite-lived intangible assets, the fair value of one of the Company’s indefinite-lived trademark intangible assets exceeded its carrying value by less than 20%. The carrying value of this trademark is $293 as of December 31, 2024.

Long-Term Debt and Credit Facil

Long-Term Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt and Credit Facilities	Long-Term Debt and Credit Facilities Long-term debt consisted of the following at December 31: Weighted Average Interest Rate Maturities 2024 2023 Notes 3.0% 2025 - 2078 $ 6,946 $ 7,580 Commercial paper 3.0% 2025 936 606 Finance Lease Obligations Various 59 53 7,941 8,239 Less: Current portion of long-term debt (652) (20) Total $ 7,289 $ 8,219 Debt payable within one year consisted of the following at December 31: 2024 2023 Notes and loans payable $ 8 $ 310 Current portion of long-term debt 652 20 Debt payable within one year $ 660 $ 330 The Company classifies commercial paper as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis. Excluding commercial paper, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2024, were as follows: Years Ended December 31, 2025 $ 652 2026 1,035 2027 509 2028 612 2029 519 Thereafter 3,678 Total $ 7,005 The Company’s debt issuances and redemptions support its capital structure strategy objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. During the year ended December 31, 2024, the Company redeemed at maturity $500 of ten-year Medium-Term Notes with a fixed coupon of 3.25%. The redemption was financed with commercial paper borrowings. In March 2023, the Company issued $500 of three-year Senior Notes at a fixed coupon rate of 4.800%, $500 of five-year Senior Notes at a fixed coupon rate of 4.600% and $500 of ten-year Senior Notes at a fixed coupon rate of 4.600%. At December 31, 2024, the Company had access to unused domestic and foreign lines of credit of $3,725 (including under the facility discussed below) and could also issue long-term debt pursuant to an effective shelf registration statement. In November 2022, the Company entered into an amended and restated $3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring November 2027, which replaced, on substantially similar terms, the Company’s $3,000 revolving credit facility that was scheduled to expire in August 2026. In November 2023, the Company extended the term of the credit facility for an additional year, expiring in November 2028. In November 2024, the Company further extended the term of the credit facility for an additional year, expiring in November 2029. Commitment fees related to the credit facility are not material.

Fair Value Measurements and Fin

Fair Value Measurements and Financial Instruments	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Company’s policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company’s treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. It is the Company’s policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged. Provided below are details of the Company’s exposures by type of risk and derivative instruments by type of hedge designation. Valuation Considerations The Company’s derivative instruments include foreign currency contracts and commodity contracts. The fair value of these instruments are classified as follows: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. Foreign Exchange Risk As the Company markets its products in over 200 countries and territories, it is exposed to currency fluctuations related to manufacturing and selling its products in currencies other than the U.S. dollar. The Company manages its foreign currency exposures through a combination of cost containment measures, sourcing strategies, selling price increases and the hedging of certain costs in an effort to minimize the impact on earnings of foreign currency rate movements. The Company primarily utilizes foreign currency contracts, including forward and swap contracts, option contracts, foreign and local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. The duration of foreign currency contracts generally does not exceed 12 months and the contracts are valued using observable market rates (Level 2 valuation). Interest Rate Risk The Company manages its targeted mix of fixed and floating rate debt with debt issuances and by entering into interest rate swaps in order to mitigate fluctuations in earnings and cash flows that may result from interest rate volatility. The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rates for future debt issuances. The notional amount, interest payment and maturity date of the swaps generally match the principal, interest payment and maturity date of the related debt, and the swaps are valued using observable benchmark rates (Level 2 valuation). Commodity Price Risk The Company is exposed to price volatility related to raw materials used in production, such as resins, essential oils, tropical oils, pulp, tallow, corn, poultry and soybeans. The Company manages its raw material exposures through a combination of cost containment measures, sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts. Futures contracts are used on a limited basis, primarily in the Hill’s Pet Nutrition segment, to manage volatility related to raw material inventory purchases of certain traded commodities, and these contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of the commodity contracts generally does not exceed 12 months. Credit Risk The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company’s policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations. The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets as of December 31, 2024 and 2023: Assets Liabilities Account Fair Value Account Fair Value Designated derivative instruments December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Foreign currency contracts Other current assets 33 19 Other accruals 22 25 Commodity contracts Other current assets — — Other accruals 1 1 Total designated $ 33 $ 19 $ 23 $ 26 Other financial instruments Marketable securities Other current assets 160 179 Total other financial instruments $ 160 $ 179 The carrying amount of cash, cash equivalents, accounts receivable and short-term debt approximated fair value as of December 31, 2024 and 2023. The estimated fair value of the Company’s long-term debt, including the current portion, as of December 31, 2024 and 2023, was $7,433 and $7,862, respectively, and the related carrying value was $7,941 and $8,239, respectively. The estimated fair value of long-term debt was derived principally from quoted prices on the Company’s outstanding fixed-term notes (Level 2 valuation). The following tables present the notional values as of: December 31, 2024 Foreign Foreign Currency Debt Commodity Contracts Fair Value Hedges $ 1,669 $ — $ — $ 1,669 Cash Flow Hedges 1,023 — 18 1,041 Net Investment Hedges 289 3,750 — 4,039 December 31, 2023 Foreign Foreign Currency Debt Commodity Contracts Fair Value Hedges $ 1,625 $ — $ — $ 1,625 Cash Flow Hedges 869 — 39 908 Net Investment Hedges 280 3,908 — 4,188 The amount of gain (loss) recognized in income associated with fair value hedges did not have a material impact on the Company’s Consolidated Financial Statements during the twelve months ended December 31, 2024. The amount of gain (loss) recognized in income and Accumulated Other Comprehensive Income (AOCI) associated with cash flow hedges did not have a material impact on the Company’s Consolidated Financial Statements during the twelve months ended December 31, 2024. The following table presents the amount of gain (loss) on net investment hedges recognized in the Company’s AOCI: Gain (Loss) Recognized in AOCI Twelve Months Ended December 31, Hedging instruments: 2024 2023 Foreign currency contracts $ 42 $ (34) Foreign currency debt 211 (124) Total gain (loss) on net investment hedges $ 253 $ (158)

Capital Stock and Stock-Based C

Capital Stock and Stock-Based Compensation Plans	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Capital Stock and Stock-Based Compensation Plans	Capital Stock and Stock-Based Compensation Plans Preference Stock The Company has the authority to issue 50,262,150 shares of preference stock. Stock Repurchases On March 10, 2022, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to $5 billion under a new share repurchase program, which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors. The Company repurchased its common stock at a cost of $1,739 during 2024. The Company may use either authorized and unissued shares or treasury shares to meet share requirements resulting from the exercise of stock options and the vesting of restricted stock unit awards. A summary of common stock and treasury stock activity for the three years ended December 31 is as follows: Common Stock Outstanding Treasury Stock Balance, January 1, 2022 840,480,284 625,226,076 Common stock acquired (17,060,788) 17,060,788 Shares issued for stock options 5,654,692 (5,654,692) Shares issued for restricted stock units and other 1,138,418 (1,138,418) Balance, December 31, 2022 830,212,606 635,493,754 Common stock acquired (14,735,909) 14,735,909 Shares issued for stock options 5,318,430 (5,318,430) Shares issued for restricted stock units and other 617,642 (617,642) Balance, December 31, 2023 821,412,769 644,293,591 Common stock acquired (18,321,422) 18,321,422 Shares issued for stock options 8,606,699 (8,606,699) Shares issued for restricted stock units and other 876,652 (876,652) Balance, December 31, 2024 812,574,698 653,131,662 Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units, based on the fair value of those awards at the date of grant. The fair value of restricted stock units, generally based on market price, is amortized ratably over the requisite service period. The estimated fair value of stock options on the date of grant, based on the Black-Scholes value described below, is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company accounts for forfeitures as they occur. Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation cost from the grant date through the date that the employee first becomes eligible to retire and is no longer required to provide service to earn the award. The Company has one incentive compensation plan pursuant to which it issues restricted stock units (both performance-based and time-vested) and stock options to employees and shares of common stock and stock options to non-employee directors. The Personnel and Organization Committee of the Board, which is comprised entirely of independent directors, administers the incentive compensation plan. The total stock-based compensation expense charged against pretax income for this plan was $135, $122 and $125 for the years ended December 31, 2024, 2023 and 2022, respectively. The total income tax benefit recognized on stock-based compensation, excluding excess tax benefits, was approximately $26, $22 and $25 for the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is recorded within Selling, general and administrative expenses in the Corporate segment as these amounts are not included in internal measures of segment operating performance. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. The weighted-average fair value assumptions are summarized in the following table: 2024 2023 2022 Expected term of options 6 years 6 years 6 years Expected volatility rate 20.5 % 19.8 % 21.1 % Risk-free interest rate 3.8 % 4.3 % 3.0 % Expected dividend yield 2.1 % 2.5 % 2.4 % Weighted-average estimated fair value $ 22.65 $ 14.89 $ 14.71 The weighted-average expected term of options granted each year was determined with reference to historical exercise and post-vesting cancellation experience, the vesting period of the awards and the contractual term of the awards, among other factors. Expected volatility incorporates implied share-price volatility derived from exchange traded options on the Company’s common stock. The risk-free interest rate for the expected term of the option is based on the yield of a zero-coupon U.S. Treasury bond with a maturity period equal to the option’s expected term. Stock Options The Company issues non-qualified stock options to non-employee directors, officers and other key employees. Stock options have a contractual term of eight years and generally vest ratably over three years. As of December 31, 2024, approximately 19,248,078 shares of common stock were available for future stock option grants. A summary of stock option activity during 2024 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Intrinsic Value of Unexercised Options outstanding, January 1, 2024 20,742 $ 75 Granted 955 106 Exercised (8,662) 74 Forfeited (240) 76 Expired (21) 73 Options outstanding, December 31, 2024 12,774 78 5 $ 176 Options exercisable, December 31, 2024 9,265 $ 76 4 $ 136 As of December 31, 2024, there was $12 of total unrecognized compensation expense related to unvested stock options, which will be recognized over a weighted-average period of 1.3 years . The total intrinsic value of options exercised during the years ended December 31, 2024, 2023 and 2022 was $150 , $28 and $47, respectively. The benefits of tax deductions in excess of grant date fair value resulting from the exercise of stock options and vesting of restricted stock unit awards for the years ended December 31, 2024, 2023 and 2022 were $18, $4 and $2, respectively, and are recognized in the provision for income taxes as a discrete item in the quarterly period in which they occur and classified as an operating cash flow. Cash proceeds received from options exercised for the years ended December 31, 2024, 2023 and 2022 were $638, $380 and $418, respectively. Performance-based Restricted Stock Units Under the Company’s long-term incentive compensation program, the Company grants officers and other key employees a target number of unearned performance-based restricted stock units at the beginning of each three-year performance cycle. Awards are earned and vest following the conclusion of the performance period on the basis of achievement of performance goals established at the commencement of each three-year performance period. A summary of performance-based restricted stock unit activity for the year ended December 31, 2024 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Performance-based restricted stock units as of January 1, 2024 1,069 $ 68 Activity: Granted 321 91 Vested (283) 70 Forfeited (89) 72 Change due to performance and/or market condition achievement 19 57 Performance-based restricted stock units as of December 31, 2024 1,037 $ 74 As of December 31, 2024, there was $32 of total unrecognized compensation expense related to unvested performance-based restricted stock unit awards, which will be recognized ratably over the remaining performance period. The Company uses a Monte-Carlo simulation model to estimate the fair value of performance-based restricted stock units at the date of grant. Time-Vested Restricted Stock Units The Company also grants time-vested restricted stock unit awards. Awards either vest at the end of the restriction period, which is generally three years from the date of grant, or ratably over the restriction period. As of December 31, 2024, approximately 7,324,623 shares of common stock were available for future restricted stock unit awards. A summary of restricted stock unit activity during 2024 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Restricted stock units as of January 1, 2024 2,174 $ 76 Activity: Granted 854 105 Vested (951) 76 Forfeited (90) 77 Restricted stock units as of December 31, 2024 1,987 $ 88 As of December 31, 2024, there was $68 of total unrecognized compensation expense related to unvested time-vested restricted stock unit awards, which will be recognized over a weighted-average period of 1.6 years. The total fair value of time-vested restricted stock units vested during the years ended December 31, 2024, 2023 and 2022 was $72, $45 and $40, respectively.

Employee Stock Ownership Plan

Employee Stock Ownership Plan	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Employee Stock Ownership Plan	Employee Stock Ownership Plan In 1989, the Company expanded its Employee Stock Ownership Plan ( “ ESOP ” ) through the introduction of a leveraged ESOP that funds certain benefits for employees who have met eligibility requirements. As of December 31, 2024 and 2023, there were 7,428,343 and 8,348,104 shares of common stock, respectively, outstanding and issued to the Company ’ s ESOP. During 2000, the ESOP entered into a loan agreement with the Company under which the benefits of the ESOP may be extended through 2035. As of December 31, 2024, the ESOP had no outstanding borrowings from the Company. Dividends on stock held by the ESOP are paid to the ESOP trust and, together with cash contributions from the Company, are (a) used by the ESOP to repay principal and interest, (b) credited to participant accounts, (c) used for contributions to the Company’s defined contribution plans or (d) used to pay the Company’s defined contribution plan expenses. Stock is allocated to participants based upon the ratio of the current year’s debt service to the sum of total outstanding principal and interest payments over the life of the debt. As of December 31, 2024, 7,334,758 shares of common stock had been released and allocated to participant accounts and 93,585 shares of common stock were available for future release and allocation to participant accounts. Dividends on the stock used to repay principal and interest or credited to participant accounts are deductible for income tax purposes and, accordingly, are reflected net of their tax benefit in the Consolidated Statements of Changes in Shareholders’ Equity. Annual expense related to the ESOP was $0 in 2024, 2023 and 2022. The Company paid dividends on the shares held by the ESOP of $16 in 2024, $17 in 2023 and $19 in 2022. The Company did not make any contributions to the ESOP in 2024, 2023 or 2022.

Retirement Plans and Other Reti

Retirement Plans and Other Retiree Benefits	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Retirement Plans and Other Retiree Benefits	Retirement Plans and Other Retiree Benefits Retirement Plans The Company and certain of its U.S. and foreign subsidiaries maintain defined benefit retirement plans. Benefits under these plans are based primarily on years of service and employees’ earnings. In the U.S., effective January 1, 2014, the Company provides virtually all future retirement benefits through the Company’s defined contribution plan. As a result, service after December 31, 2013 is not considered for participants in the Company’s principal U.S. defined benefit retirement plan. Participants in the Company’s principal U.S. defined benefit retirement plan whose retirement benefit was determined under the cash balance formula continue to earn interest credits on their vested balances as of December 31, 2013 but no longer receive pay credits. Participants whose retirement benefit was determined under the final average earnings formula or career average earnings formula continue to have their accrued benefit adjusted for pay increases until termination of employment. In the first quarter of 2023, the Company recorded a charge of $267 as a result of a decision of the United States Court of Appeals for the Second Circuit (the “Second Circuit”) affirming a grant of summary judgment to the plaintiffs in a lawsuit under the Employee Retirement Income Security Act seeking the recalculation of benefits and other relief associated with a 2005 residual annuity amendment to the Colgate-Palmolive Company Employees’ Retirement Income Plan (the “Retirement Plan”). The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. See Note 12, Commitments and Contingencies for additional information. In the Company’s principal U.S. plans and certain funded foreign plans, funds are contributed to trusts in accordance with regulatory limits to provide for current service and for any unfunded projected benefit obligation over a reasonable period. The target asset allocation for the Company’s defined benefit plans is as follows: United States International Asset Category Equity securities 26 % 17 % Fixed income securities 60 % 63 % Other investments 14 % 20 % Total 100 % 100 % At December 31, 2024, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Cash and cash equivalents Level 1 $ 226 $ 21 U.S. common stocks Level 1 1 2 International common stocks Level 1 — 15 Pooled funds (1) Level 1 35 103 Fixed income securities (2) Level 2 624 75 Guaranteed investment contracts (3) Level 2 — 30 886 246 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 223 28 Fixed income funds (5) 68 222 Hedge funds (6) — 7 Multi-asset funds (7) 157 2 Real estate funds (8) — 27 448 286 Other assets and liabilities, net (9) (39) 5 Total Investments $ 1,295 $ 537 At December 31, 2023, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Cash and cash equivalents Level 1 $ 206 $ 14 U.S. common stocks Level 1 — 2 International common stocks Level 1 — 20 Pooled funds (1) Level 1 20 113 Fixed income securities (2) Level 2 710 71 Guaranteed investment contracts (3) Level 2 — 34 936 254 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 315 55 Fixed income funds (5) 99 219 Hedge funds (6) — 7 Multi-asset funds (7) 40 1 Real estate funds (8) — 30 454 312 Other assets and liabilities, net (9) (30) — Total Investments $ 1,360 $ 566 (1) Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities. (2) The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2024 and December 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds. (3) The guaranteed investment contracts (“GICs”) represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption. (4) Investments that are measured at fair value using net asset value (“NAV”) per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly. (5) Fixed income funds primarily invest in U.S. government and investment grade corporate bonds. (6) Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options. (7) Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies. (8) Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager. (9) This category primarily includes unsettled trades for investments purchased and sold and interest receivables. Equity securities in the U.S. defined benefit retirement plans did not include any investment in the Company’s common stock at either December 31, 2024 or December 31, 2023. No shares of the Company’s stock were purchased by the U.S. plans in 2024 or 2023. The plans received no dividends on the Company’s common stock in either 2024 or 2023. Other Retiree Benefits The Company and certain of its subsidiaries provide, to the extent not otherwise provided by government-sponsored plans, health and life insurance benefits or subsidies for retired employees who meet applicable eligibility requirements. The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2024 2023 2024 2023 2024 2023 United States International Change in Benefit Obligations Benefit obligations at beginning of year $ 1,922 $ 1,673 $ 776 $ 675 $ 665 $ 658 Service cost 1 — 16 15 7 7 Interest cost 99 91 33 33 36 38 Participants’ contributions — — 5 5 — — Plan amendments — — — — — (33) Actuarial loss (gain) (54) 36 (11) 65 (14) 38 Foreign exchange impact — — (40) 29 (8) 4 Termination benefits 5 3 — 2 — — Curtailments and settlements (1) — (18) (6) — — Benefit payments (141) (148) (41) (42) (54) (47) ERISA litigation matter — 267 — — — — Benefit obligations at end of year $ 1,831 $ 1,922 $ 720 $ 776 $ 632 $ 665 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,360 $ 1,363 $ 566 $ 516 $ — $ — Actual return on plan assets 49 115 18 26 — — Company contributions 29 30 37 39 54 47 Participants’ contributions — — 5 5 — — Foreign exchange impact — — (31) 27 — — Settlements and acquisitions (2) — (17) (5) — — Benefit payments (141) (148) (41) (42) (54) (47) Fair value of plan assets at end of year $ 1,295 $ 1,360 $ 537 $ 566 $ — $ — Funded Status Benefit obligations at end of year $ 1,831 $ 1,922 $ 720 $ 776 $ 632 $ 665 Fair value of plan assets at end of year 1,295 1,360 537 566 — — Net amount recognized $ (536) $ (562) $ (183) $ (210) $ (632) $ (665) Amounts Recognized in Balance Sheet Noncurrent assets $ 1 $ 1 $ 47 $ 48 $ — $ — Current liabilities (27) (28) (15) (15) (51) (53) Noncurrent liabilities (510) (535) (215) (243) (581) (612) Net amount recognized $ (536) $ (562) $ (183) $ (210) $ (632) $ (665) Amounts Recognized in Accumulated Other Comprehensive Income (Loss) Actuarial loss $ 710 $ 767 $ 174 $ 177 $ 109 $ 128 Transition/prior service cost(credit) — — 8 9 (159) (180) $ 710 $ 767 $ 182 $ 186 $ (50) $ (52) Accumulated benefit obligation $ 1,818 $ 1,907 $ 668 $ 719 $ — $ — Pension Plans Other Retiree Benefit Plans 2024 2023 2024 2023 2024 2023 United States International Weighted-Average Assumptions Used to Determine Benefit Obligations Discount rate 5.73 % 5.40 % 4.69 % 4.35 % 5.74 % 5.37 % Long-term rate of compensation increase 3.50 % 3.50 % 3.36 % 3.19 % — % — % ESOP growth rate — % — % — % — % 6.00 % 6.00 % Medical cost trend rate of increase — % — % — % — % 7.00 % 6.00 % Interest Crediting Rate 5.58 % 4.99 % 3.23 % 1.13 % — % — % The actuarial gains recorded during 2024 for both the U.S. pension and Other retiree benefit plans were primarily a result of an increase in discount rates applied against future estimated benefit payments that resulted in a decrease in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The actuarial losses recorded during 2023 for both the U.S. pension and Other retiree benefit plans were primarily a result of a decrease in discount rates applied against future estimated benefit payments that resulted in an increase in the benefit obligation for both the U.S. pension and Other retiree benefit plans. The overall investment objective of the plans is to balance risk and return so that obligations to employees are met. The Company evaluates its expected long-term rate of return on plan assets on an annual basis. In determining the expected long-term rate of return, the Company considers the nature of the plans’ investments and the historical rates of return. The assumed expected long-term rate of return on plan assets for U.S. pension plans was 6.50% as of December 31, 2024 and December 31, 2023. Average annual rates of return on plan assets for the U.S. pension plans for the most recent 1-year, 5-year, 10-year, 15-year and 25-year periods were 5%, 2%, 4%, 6% and 5%, respectively. Similar assessments were performed in determining rates of return on international pension plan assets to arrive at the Company’s 2024 weighted-average expected long-term rate of return on plan assets of 5.69%. The medical cost trend rate of increase assumed in measuring the expected cost of benefits is projected to decrease from 7.00% in 2025 to 5.00% by 2030, remaining at 4.50% for the years thereafter. Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following: 2024 2023 Benefit Obligation Exceeds Fair Value of Plan Assets Projected benefit obligation $ 2,251 $ 2,352 Fair value of plan assets 1,486 1,532 Accumulated benefit obligation 2,075 2,204 Fair value of plan assets 1,345 1,428 Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following: 2024 2023 Benefit Obligation Exceeds Fair Value of Plan Assets Accumulated postretirement benefit obligation $ 632 $ 665 Fair value of plan assets — — Summarized information regarding the net periodic benefit costs for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2024 2023 2022 2024 2023 2022 2024 2023 2022 United States International Components of Net Periodic Benefit Cost Service cost $ 1 $ — $ — $ 16 $ 15 $ 15 $ 7 $ 7 $ 18 Interest cost 99 91 64 33 33 21 36 38 36 Expected return on plan assets (85) (79) (101) (29) (25) (21) — — — Amortization of transition and prior service costs (credits) — — — 1 1 1 (21) (20) (6) Amortization of actuarial loss 39 43 46 5 5 7 4 1 14 Net periodic benefit cost $ 54 $ 55 $ 9 $ 26 $ 29 $ 23 $ 26 $ 26 $ 62 Other postretirement charges 5 3 13 — 2 4 — — 2 ERISA litigation matter — 267 — — — — — — — Total pension cost $ 59 $ 325 $ 22 $ 26 $ 31 $ 27 $ 26 $ 26 $ 64 Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost Discount rate 5.40 % 5.66 % 2.98 % 4.61 % 4.75 % 2.10 % 5.37 % 5.67 % 3.06 % Expected long-term rate of return on plan assets 6.50 % 6.25 % 5.70 % 5.69 % 4.66 % 2.72 % N/A N/A N/A Long-term rate of compensation increase 3.50 % 3.50 % 3.50 % 3.24 % 3.22 % 2.89 % — % — % — % ESOP growth rate — % — % — % — % — % — % 6.00 % 6.00 % 6.00 % Medical cost trend rate of increase — % — % — % — % — % — % 6.00 % 6.25 % 6.00 % Interest Crediting Rate 4.99 % 5.21 % 2.82 % 0.64 % 2.28 % 0.84 % — % — % — % The service related component of pension and other postretirement benefit costs is included in Operating profit. The non-service related components (interest cost, expected return on assets, amortization of transition and prior service costs and credits and amortization of actuarial gains and losses) are included in the line item “Non-service related postretirement costs,” which is below Operating profit. The Company made no voluntary contributions in 2024, 2023 and 2022. Expected Contributions and Benefit Payments At present, the Company does not expect to make any voluntary contributions to its U.S. postretirement plans for the year ending December 31, 2025. Actual funding may differ from current estimates depending on the variability of the market value of the assets, changes in the benefit obligations and other market or regulatory conditions. Benefit payments expected to be paid from the Company’s assets to participants in unfunded plans are estimated to be approximately $95 for the year ending December 31, 2025. Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows: Pension Plans Years Ended December 31, United States International Other Retiree Benefit Plans Total 2025 $ 377 $ 42 $ 52 471 2026 143 41 54 238 2027 143 43 55 241 2028 142 45 55 242 2029 141 46 55 242 2030-2034 653 247 274 1,174

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of Income before income taxes are as follows for the years ended December 31: 2024 2023 2022 United States $ 1,084 $ 692 $ 1,169 International 2,872 2,700 1,491 Total Income before income taxes $ 3,956 $ 3,392 $ 2,660 The Provision for income taxes consists of the following for the years ended December 31: 2024 2023 2022 United States $ 188 $ 72 $ 199 International 719 865 494 Total Provision for income taxes $ 907 $ 937 $ 693 Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows: 2024 2023 2022 Goodwill and intangible assets $ 3 $ 1 $ 106 Property, plant and equipment 12 (13) 2 Pension and other retiree benefits (6) 68 (1) Stock-based compensation (14) 2 (3) Right-of-use assets/lease liabilities 2 1 (5) Tax credits and tax loss carryforwards, net of valuation allowance 37 29 8 Deferred withholding tax (14) 7 8 Research and Experimentation Capitalization 21 29 58 Other, net (8) 11 (10) Total deferred tax benefit (provision) $ 33 $ 135 $ 163 The difference between the statutory U.S. federal income tax rate and the Company’s global effective tax rate as reflected in the Consolidated Statements of Income is as follows: 2024 2023 2022 Percentage of Income before income taxes Tax at United States statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 0.5 (0.1) 0.8 Earnings taxed at other than United States statutory rate 4.1 5.4 5.4 Non-deductible goodwill impairment charges — — 1.9 Foreign-derived intangible income benefit (2.6) (2.4) (2.6) Foreign tax matter — 3.7 — Other, net (0.1) — (0.4) Effective tax rate 22.9 % 27.6 % 26.1 % The components of deferred tax assets (liabilities) are as follows at December 31: 2024 2023 Deferred tax liabilities: Goodwill and intangible assets $ (389) $ (412) Property, plant and equipment (397) (420) Right-of-use assets (126) (126) Deferred withholding tax (110) (96) Other (130) (34) Total deferred tax liabilities (1,152) (1,088) Deferred tax assets: Pension and other retiree benefits 272 295 Tax credits and tax loss carryforwards 430 356 Lease liabilities 137 134 Accrued liabilities 223 221 Stock-based compensation 61 75 Research and Experimentation Capitalization 108 87 Other 101 60 Total deferred tax assets 1,332 1,228 Valuation Allowance $ (328) $ (287) Net deferred tax assets $ 1,004 $ 941 Net deferred income taxes $ (148) $ (147) The changes in valuation allowance for deferred tax assets are as follows: 2024 2023 2022 Balance, January 1 $ 287 $ 129 $ 120 Additions Charged to costs and expenses 56 158 14 Deductions 15 — 5 Balance, December 31 $ 328 $ 287 $ 129 As of December 31, 2024, the Company had net operating losses (“NOLs”) and capital loss carryforwards of $37. Of this amount, capital loss and NOL carryforwards of $6 will begin to expire in 2025 and NOLs of $13 can be carried forward indefinitely. The Company believes that it will be able to utilize these capital loss and NOL carryforwards. There is an additional NOL of $18 which has a full valuation allowance. As of December 31, 2024, the Company has $393 of tax credits, of which $66 will begin to expire in 2030 and $17 can be carried forward indefinitely. The Company believes that it will be able to utilize these tax credits. The remaining credits of $310 have a full valuation allowance. Applicable U.S. income and foreign withholding taxes have been provided on substantially all of the Company’s accumulated earnings of foreign subsidiaries. Net tax expense of $55, net tax benefit of $19 and net tax expense of $164 were recorded directly through equity in 2024, 2023 and 2022 respectively. The net tax expense or benefit in each year predominantly includes current and future tax impacts related to benefit plans and the impact of currency translation adjustments. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Unrecognized tax benefits: Balance, January 1 $ 314 $ 298 $ 245 Increases as a result of tax positions taken during the current year 37 73 32 Decreases of tax positions taken during prior years (53) (61) (21) Increases of tax positions taken during prior years 10 6 46 Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations (3) (2) (2) Effect of foreign currency rate movements (9) — (2) Balance, December 31 $ 296 $ 314 $ 298 If all of the unrecognized tax benefits for 2024 above were recognized, approximately $286 would impact the effective tax rate. It is reasonably possible that the amount of unrecognized benefits with respect to our uncertain tax positions could change in the next twelve months and such change may or may not be material. The Company recognized expenses of approximately $22, $10 and $8 for interest and penalties related to the above unrecognized tax benefits within income tax expense in 2024, 2023 and 2022, respectively. The Company had accrued interest and penalties of approximately $68, $45 and $40 as of December 31, 2024, 2023 and 2022, respectively. In the third quarter of 2023, the Internal Revenue Service (the “IRS”) issued a notice giving taxpayers temporary relief from the effects of certain U.S. tax regulations that were issued in December 2021, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-source income. This notice allowed taxpayers to defer the application of these new regulations through the end of 2023. In December 2023, the IRS issued further guidance modifying this temporary relief period to the date that a notice or other guidance withdrawing or modifying the temporary relief is issued. The Company will recognize the impact, if any, in the period in which the temporary relief is withdrawn or modified. During the quarter ended June 30, 2023, the Company reassessed with its legal and tax advisers certain tax deductions taken in prior years by one of our subsidiaries and concluded that it was more likely than not that the deductions would not be sustained by the courts in that jurisdiction. The value of the tax deductions was not material to the Company in any year in which they were taken. The cumulative effect of the change in tax position of $148 was reflected as a discrete item in the quarter ended June 30, 2023 income tax expense, partially offset by the reversal of certain prior years’ withholding tax reserves of $22 that were no longer required. The tax liability was paid in the quarter ended September 30, 2023. On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”) was enacted, which among other things, implements a 15% minimum tax on book income of certain large corporations effective for years beginning after December 31, 2022. Based on the Company’s analysis, as well as guidance published by the IRS, the IRA, and in particular the 15% minimum tax, did not have an impact on the Company’s Consolidated Financial Statements. Subsequent to the aforementioned guidance published by the IRS, on September 12, 2024, the U.S. Treasury Department and IRS released proposed regulations relating to this 15% minimum tax. Based on the Company’s analysis, these proposed regulations, if finalized in their current form, are not expected to have an impact on the Company’s Consolidated Financial Statements. However, the Company will continue to evaluate any additional guidance and clarification that becomes available. Additionally, on December 15, 2022, the 27 member states of the European Union (“EU”) reached an agreement on a minimum level of taxation for certain large corporations to pay a minimum corporate tax rate of 15% in every jurisdiction in which they operate. This agreement, which is known as the Minimum Tax Directive (part of the “Pillar II Model Rules”), was supposed to be transposed into the laws of all EU member states by December 31, 2023. Most member states complied, while some were granted extensions of time. In addition, many other jurisdictions outside the EU have implemented a similar minimum tax regime consistent with the policy of the Pillar II Model Rules. Detailed regulations of these minimum tax regimes are still being considered in certain countries and, in some cases, enactment and timing is still uncertain. Based on current legislation and available guidance, apart from a significant additional compliance burden, Pillar II did not have a material impact as of December 31, 2024 and the Company does not believe it will have a material impact on its Consolidated Financial Statements. However, as these rules and related regulations are revised and implemented, the Company will evaluate the impact, if any, on its Consolidated Financial Statements. The Company has ongoing federal, state and international income tax audits in various jurisdictions and evaluates uncertain tax positions that may be challenged by local tax authorities and not fully sustained. All U.S. federal income tax returns through December 31, 2013 have been audited by the IRS and there are limited matters which the Company plans to appeal for years 2010 through 2013. One such matter relates to the IRS assessment of taxes on the Company by imputing income on certain activities within one of our international operations, which is also under audit for the years 2014 through 2018. There were U.S. Tax Court rulings during 2023 in favor of the IRS against unrelated third parties on similar matters. Despite the U.S. Tax Court rulings, the Company continues to believe that the tax assessment against the Company is without merit. While there can be no assurances, the Company believes this matter will ultimately be decided in favor of the Company. The amount of tax plus interest for the years 2010 through 2018 is estimated to be approximately $153, which is not included in the Company’s uncertain tax positions. In May 2024, the IRS initiated an audit for the years 2019 through 2021. The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share For the years ended December 31, 2024, 2023 and 2022, earnings per share were as follows: 2024 2023 2022 Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Basic EPS $ 2,889 819.1 $ 3.53 $ 2,300 827.4 $ 2.78 $ 1,785 836.4 $ 2.13 Stock options and restricted stock units 4.1 1.8 2.4 Diluted EPS $ 2,889 823.2 $ 3.51 $ 2,300 829.2 $ 2.77 $ 1,785 838.8 $ 2.13 Basic earnings per common share is computed by dividing net income available for common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding stock options and restricted stock units. For the years ended December 31, 2024, 2023 and 2022, the average number of stock options that were anti-dilutive and not included in diluted earnings per share calculations were 295,968, 13,719,286 and 5,236,371, respectively. For the years ended December 31, 2024, 2023 and 2022, the average number of restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 100,191, 1,183 and 155,118, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies As of December 31, 2024, the Company has various contractual commitments for future multi-year purchases of raw, packaging and other materials and services totaling approximately $568. As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. In addition, management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites. The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances. The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is $0 to approximately $250 (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate range may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above. Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year. Brazilian Matters There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the “Seller”). The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately $93. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001. In each of September 2015, February 2017, September 2018, April 2019 and August 2020, the Company lost an administrative appeal and subsequently challenged these assessments in the Brazilian federal courts. Currently, there are three lawsuits pending in the Lower Federal Court and two cases have progressed to the Federal Court of Appeals. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the disallowances and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously. In November 2023, based upon changes in Brazilian tax law, the Company filed petitions in three of the actions requesting that the penalty portion of the claim be removed. The Brazilian tax authority agreed with the Company's position and in August 2024 reduced its claim in two of those actions and in October 2024 reduced its claim in the third. In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the action and that the Company should ultimately prevail. The Company is challenging this action vigorously. In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately $47, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that it has strong legal grounds to contest the tax assessment and that the Company should ultimately prevail. The Company is challenging this assessment vigorously. In addition, in April 2024, based upon changes in Brazilian tax law, the Company filed a petition in this matter requesting that the penalty portion of the claim be removed. The Brazilian tax authority has not yet responded to that petition. Talcum Powder Matters The Company has been named as a defendant in civil actions alleging that certain of its talcum powder products were contaminated with asbestos and/or caused mesothelioma and other cancers. Many of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos. As of December 31, 2024, there were 309 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 279 cases as of December 31, 2023. During the year ended December 31, 2024, 142 new cases were filed and 111 cases were resolved by voluntary dismissal, settlement or dismissal by the court, and one case was removed from the case count when it was established that the claim does not relate to talcum powder. The value of the settlements in the periods presented was not material, either individually or in the aggregate, to such periods’ results of operations. During the three months ended March 31, 2024, one case resulted in a jury verdict in favor of the Company after a trial. Subsequently, the trial court granted plaintiffs’ motion for a new trial in that case. However, during the three months ended September 30, 2024, an appellate court granted the Company’s request to reinstate the jury’s verdict in favor of the Company. Plaintiffs are challenging that ruling and separately are appealing other issues related to the verdict. A significant portion of the Company’s costs incurred in defending and resolving these claims has been, and the Company believes that a portion of the costs will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions, policy limits and insurance carrier insolvencies. While the Company and its legal counsel believe that the Company has strong legal grounds to contest these cases and intends to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters. ERISA Matter In June 2016, a lawsuit was filed in the United States District Court for the Southern District of New York (the “District Court”) against the Retirement Plan, the Company and certain individuals (the “Company Defendants”) claiming that residual annuity payments associated with a 2005 residual annuity amendment to the Retirement Plan were improperly calculated for certain Retirement Plan participants in violation of ERISA. The relief sought included recalculation of benefits, pre- and post-judgment interest and attorneys’ fees. This action was certified as a class action in July 2017. In July 2020, the District Court dismissed certain claims, and in August 2020 granted the plaintiffs’ motion for summary judgment on the remaining claims. In September 2020, the Company appealed to the Second Circuit. In March 2023, the Second Circuit affirmed the grant of summary judgment to the plaintiffs. In light of the Second Circuit decision, the Company recorded a charge to earnings of $267 in the quarter ended March 31, 2023, which is comprised of the recalculation of benefits and interest. Possible additional charges associated with this matter are expected to be immaterial and, where estimable, are reflected in the range of reasonably possible losses disclosed above. The decision resulted in an increase in the obligations of the Retirement Plan, which based on the current funded status of the Retirement Plan and depending on further developments in the litigation, may require a cash contribution by the Company in 2025. In June 2023, the Company filed a petition for certiorari to the United States Supreme Court requesting permission for an appeal to that court and that petition was denied in October 2023. Also, in June 2023, the plaintiffs filed a motion to enter a revised final judgment in the District Court to address certain unresolved calculation issues, which the Company opposed. In March 2024, the District Court granted the plaintiffs’ motion and found for the plaintiffs on those calculation issues. The Company has appealed that decision to the Second Circuit.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition. The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia. In connection with management changes, the Company realigned the reporting structure of its skin health business effective July 1, 2024. Accordingly, commencing with the quarter ended September 30, 2024, the results of the skin health business previously reported within the Europe reportable operating segment are reported with the other skin health businesses in the North America reportable operating segment, with no impact on the Company's consolidated results of operations or financial position. The Company has recast its historical geographic segment information to conform to the new reporting structure. The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes. The Chairman of the Board, President and Chief Executive Officer has been determined to be the Company’s Chief Operating Decision Maker who uses Operating Profit to assess performance and to allocate resources for each of the reportable operating segments in the budgeting and forecasting process. Asset information by segment is not utilized for purposes of assessing performance or allocating resources, and therefore such information has not been presented. The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments. Approximately two-thirds of the Company’s Net sales are generated from markets outside the U.S., with approximately 45% of the Company’s Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). Oral, Personal and Home Care sales to Walmart, Inc. and its affiliates represent approximately 11% of the Company’s Net sales in each of the years 2024, 2023 and 2022. No other customer represented more than 10% of Net sales in any period presented. In 2024, Corporate Operating profit Operating profit 2024 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,113 $ 1,571 $ 1,668 $ 36 $ 839 Latin America 4,782 1,933 1,328 (5) 1,526 Europe 2,770 1,050 1,031 31 658 Asia Pacific 2,858 1,078 997 (30) 812 Africa/Eurasia 1,095 432 395 16 253 Total Oral, Personal and Home Care 15,618 4,088 Pet Nutrition (2) 4,483 1,869 1,641 8 965 Reconciliation with Total Company Operating Profit Corporate (784) Total $ 20,101 $ 4,268 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,640 in 2024. (2) Net sales in the U.S. for Pet Nutrition were $3,059 in 2024. (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2023 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,091 $ 1,588 $ 1,594 $ 37 $ 871 Latin America 4,640 1,977 1,241 5 1,417 Europe 2,571 1,069 899 31 573 Asia Pacific 2,782 1,108 925 (18) 767 Africa/Eurasia 1,083 442 377 9 254 Total Oral, Personal and Home Care 15,167 3,882 Pet Nutrition (2) 4,290 1,964 1,493 26 806 Reconciliation with Total Company Operating Profit Corporate $ (704) Total $ 19,457 $ 3,984 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,625 in 2023. (2) Net sales in the U.S. for Pet Nutrition were $2,918 in 2023. (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2022 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,002 $ 1,649 $ 1,567 $ 46 $ 741 Latin America 3,982 1,885 1,059 (71) 1,108 Europe 2,362 1,023 778 28 534 Asia Pacific 2,826 1,160 954 (24) 737 Africa/Eurasia 1,082 447 389 18 228 Total Oral, Personal and Home Care 14,254 3,348 Pet Nutrition (2) 3,713 1,569 1,287 7 850 Reconciliation with Total Company Operating Profit Corporate $ (1,305) Total $ 17,967 $ 2,893 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,511 in 2022. (2) Net sales in the U.S. for Pet Nutrition were $2,432 in 2022 (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2024 2023 2022 Capital expenditures Oral, Personal and Home Care North America $ 52 $ 46 $ 66 Latin America 126 146 121 Europe 63 44 31 Asia Pacific 64 65 60 Africa/Eurasia 12 10 30 Total Oral, Personal and Home Care 317 311 308 Pet Nutrition 143 301 297 Corporate 101 93 91 Total Capital expenditures $ 561 $ 705 $ 696 2024 2023 2022 Depreciation and amortization Oral, Personal and Home Care North America $ 124 $ 116 $ 128 Latin America 100 98 93 Europe 65 65 68 Asia Pacific 81 84 89 Africa/Eurasia 8 9 9 Total Oral, Personal and Home Care 378 372 387 Pet Nutrition 132 101 65 Corporate 95 94 93 Total Depreciation and amortization $ 605 $ 567 $ 545 2024 2023 Long-lived assets (1) United States $ 2,728 $ 2,733 International 2,223 2,340 Total Long-lived assets $ 4,951 $ 5,073 (1)

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases The Company enters into leases for land, office space, warehouses and equipment. A number of the leases include one or more options to renew the lease terms, purchase the leased property or terminate the lease. The exercise of these options is at the Company’s discretion and is therefore recognized on the balance sheet when it is reasonably certain the Company will exercise such options. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date. Substantially all of the Company’s leases are considered operating leases. Finance leases were not material as of December 31, 2024 and 2023. As of December 31, 2024 and 2023, the Company’s right-of use assets and liabilities for operating leases were as follows: 2024 2023 Other assets $ 529 $ 491 Other accruals 107 95 Other liabilities 456 420 Total operating lease liabilities $ 563 $ 515 Lease liabilities for operating leases as of December 31, 2024 were as follows: 2025 $ 126 2026 108 2027 101 2028 80 2029 58 Thereafter 182 Total lease commitments $ 655 Less: Interest (92) Present value of lease liabilities $ 563 The components of the Company’s operating lease cost for the twelve months ended December 31, 2024 and 2023 were as follows: 2024 2023 Operating lease cost $ 144 $ 136 Short-term lease cost 3 3 Variable lease cost 19 20 Sublease Income (2) (2) Total lease cost $ 164 $ 157 Short-term lease cost represents the Company’s cost with respect to leases with a duration of 12 months or less and is not reflected on the Company’s Consolidated Balance Sheets. Variable lease costs are comprised of costs, such as the Company’s proportionate share of actual costs for utilities, common area maintenance, property taxes and insurance, that are not included in the lease liability and are recognized in the period in which they are incurred. Supplemental cash flow information related to operating leases for the twelve months ended December 31, 2024 and 2023 was as follows: ▪ Payments against amounts included in the measurement of lease liabilities: $132 and $171, respectively ▪ Lease assets obtained in exchange for lease liabilities: $141 and $139, respectively. As of December 31, 2024 and 2023, the weighted-average remaining lease term for operating leases was 7 and 8 years, respectively, and the weighted-average discount rate for operating leases was 4.4% and 4.5%, respectively.

Supplier Finance Program

Supplier Finance Program	12 Months Ended
	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Supplier Finance Program	Supplier Finance Program The Company has agreements to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third-party financial institutions. Participating suppliers may, at their sole discretion, elect to finance one or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company’s obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers’ decisions to finance amounts under these arrangements. The outstanding payment obligations under the Company’s supplier finance programs are included in Accounts Payable in the Consolidated Balance Sheets and were not material as of December 31, 2024 or 2023.

Supplemental Income Statement I

Supplemental Income Statement Information	12 Months Ended
	Dec. 31, 2024
Supplemental Income Statement Elements [Abstract]
Supplemental Income Statement Information	Supplemental Income Statement Information Other (income) expense, net 2024 2023 2022 Amortization of intangible assets $ 75 $ 72 $ 80 Equity income (22) (17) (12) 2022 Global Productivity Initiative 59 24 90 Product recall costs — 25 — Losses (gains) from marketable securities and other assets 6 11 (22) Indirect tax payments (refunds) 27 18 (14) Gain on the sale of land in Asia Pacific — — (47) Acquisition-related costs — — 19 Other, net 19 58 (25) Total Other (income) expense, net $ 164 $ 191 $ 69 2024 2023 2022 Research and development $ 355 $ 343 $ 320 Advertising $ 2,720 $ 2,371 $ 1,997

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Inventories by major class are as follows at December 31: Inventories 2024 2023 Raw materials and supplies $ 631 $ 606 Work-in-process 46 46 Finished goods 1,431 1,411 Total Inventories, net $ 2,108 $ 2,063 Non-current inventory, net (121) (129) Current Inventories, net $ 1,987 $ 1,934 Inventories valued under LIFO amounted to $453 and $471 at December 31, 2024 and 2023, respectively. The excess of current cost over LIFO cost at the end of each year was $105 and $120, respectively. The liquidations of LIFO inventory quantities had no material effect on income in 2024, 2023 and 2022. Inventory classified as non-current at December 31, 2024 was recorded on the Consolidated Balance Sheets as “Other assets.” Property, plant and equipment, net 2024 2023 Land $ 226 $ 227 Buildings 2,056 2,047 Manufacturing machinery and equipment 6,265 6,365 Other equipment 1,580 1,647 10,127 10,286 Accumulated depreciation (5,705) (5,704) Total Property, plant and equipment, net $ 4,422 $ 4,582 Other current assets 2024 2023 Marketable securities $ 160 $ 179 Prepaids 520 595 Derivatives 33 19 Total Other current assets $ 713 $ 793 Other accruals 2024 2023 Accrued advertising and consumer and trade promotions $ 912 $ 882 Accrued payroll and employee benefits 437 403 Accrued taxes other than income taxes 162 167 Restructuring accrual 15 11 Pension and other retiree benefits 93 96 Lease liabilities due in one year 107 95 Accrued interest 72 78 Derivatives 23 26 Dividend payable 408 — Other 662 619 Total Other accruals $ 2,891 $ 2,377 Other liabilities 2024 2023 Pension and other retiree benefits $ 1,306 $ 1,390 Long-term lease liabilities 456 420 Restructuring accrual 29 — Other 320 305 Total Other liabilities $ 2,111 $ 2,115

Supplemental Other Comprehensiv

Supplemental Other Comprehensive Income (Loss) Information	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Supplemental Other Comprehensive Income (Loss) Information	Supplemental Other Comprehensive Income (Loss) Information Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows: 2024 2023 2022 Cumulative translation adjustments: Cumulative translation adjustments, pre-tax $ (298) $ 127 $ (113) Tax amounts (37) 13 (29) Cumulative translation adjustments, net of tax (335) 140 (142) Pension and other benefits: Net actuarial gain (loss), prior service costs and settlements 31 (49) 466 Amortization of net actuarial loss, transition and prior service costs (1) 28 30 62 Retirement Plan and other retiree benefit adjustments, pre-tax 59 (19) 528 Tax amounts (16) 3 (115) Retirement Plan and other retiree benefit adjustments, net of tax 43 (16) 413 Cash flow hedges: Gains (losses) on cash flow hedges, pre-tax 10 (10) 80 Tax amounts (2) 3 (20) Gains (losses) on cash flow hedges, net of tax 8 (7) 60 Total Other comprehensive income (loss), net of tax $ (284) $ 117 $ 331 (1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details. There were no tax impacts on Other comprehensive income (loss) attributable to Noncontrolling interests. Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) is comprised of cumulative foreign currency translation gains and losses, unrecognized pension and other retiree benefit costs and unrealized gains and losses from derivative instruments designated as cash flow hedges. At December 31, 2024 and 2023, Accumulated other comprehensive income (loss) consisted primarily of aftertax unrecognized pension and other retiree benefit costs of $605 and $647, respectively, and aftertax cumulative foreign currency translation losses of $3,687 and $3,351, respectively. Foreign currency translation adjustments in 2024 primarily reflect losses from the Euro, Brazilian Real and Mexican Peso. Foreign currency translation adjustments in 2023 primarily reflect gains from the Euro, Mexican Peso and Brazilian Real.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 2,889	$ 2,300	$ 1,785

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Management’s Role in Assessing and Managing Cybersecurity Risk; Processes for assessing, identifying and managing material risks from cybersecurity threats We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management (“ERM”) Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management. The ERM Committee monitors both current and emerging risks facing the Company and meets at least quarterly to review the prioritization of identified risks. The ERM Committee has identified cybersecurity as a critical risk facing the Company. Each of the most critical risks identified is assigned to a member of senior management who oversees the management, mitigation and presentation of the risk to the senior leadership team and throughout the year to our Board of Directors. The risks relating to information technology, including cybersecurity, are overseen by our Chief Information Officer. Our Chief Information Officer then assigns the risks within the Information Technology risk category to others on his team. The cybersecurity risk is managed and overseen by our Chief Information Security Officer (“CISO”), who reports to our Chief Information Officer. Cybersecurity as a risk is presented to the full ERM Committee annually or more frequently as needed. We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats. Our Chief Information Officer reports to our Group President, Growth and Strategy, a member of our senior leadership team who reports to our Chairman of the Board, President and Chief Executive Officer. Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company’s systems and information. Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy. The Company’s information security organization seeks to employ cybersecurity best practices, including implementing new technologies to proactively identify and monitor new vulnerabilities and reduce risk, conducting due diligence of third-party vendors’ information security programs, maintaining security policies and standards and regularly updating and testing our response planning and protocols. The information security organization also works in partnership with our Internal Audit function to identify cybersecurity risks and review cybersecurity-related internal controls with third parties as part of the overall internal controls process. The information security organization also gains valuable information to improve our threat and risk awareness capabilities as a member of an industry information sharing and analysis organization, which provides strategic and tactical information sharing channels. Additionally, employees are provided mandatory cybersecurity awareness training on an annual basis, which includes information about how to identify and report cybersecurity concerns and incidents. The information security organization also conducts phishing simulations and testing scenarios through tabletop exercises and assessment activities, to help ensure compliance with our cyber policies and procedures. We maintain a cybersecurity insurance policy and have retained relevant incident response services. Additionally, we maintain an offensive security team that works both independently and with third party cybersecurity professionals to conduct security assessments of our enterprise-wide cybersecurity practices, including penetration testing, and identify areas for continuous improvement within the information security program. The Company is a member of the Retail and Hospitality Information Sharing and Analysis Center, which provides additional intelligence associated with threats pertaining to our industry. We maintain a Data Security Incident Response Plan (the “Plan”), which outlines the processes and procedures that we should follow to respond to, remediate and resolve a security incident involving a potential or actual compromise of our proprietary information and/or personal information. It also describes the structure, roles and responsibilities of personnel involved in responding to such incidents and provides a process for alerting senior management of such incidents. The Plan is reviewed on an annual basis and revised as necessary. Our dedicated information security organization leverages various frameworks for managing cybersecurity risks, including the National Institute of Standards and Technology (“NIST”) framework. The key pillars of the NIST framework are to (i) develop an organizational understanding to manage cybersecurity risk to systems, people, assets, data and capabilities; (ii) develop and implement appropriate safeguards to ensure delivery of critical services; (iii) develop and implement appropriate activities to identify the occurrence of a cybersecurity event; (iv) develop and implement appropriate activities to maintain plans for resilience and to restore any capabilities or services that were impaired due to a cybersecurity incident; and (v) develop appropriate activities to action an incident. We have a comprehensive third party cybersecurity risk review process, which prioritizes, monitors and assesses the risks associated with our third party service provider interactions. The third party service provider assessment framework follows industry standard practices and allows us to properly understand the risk associated with the services provided which are key to our company’s daily operations. For additional information regarding risks faced by the Company from cybersecurity threats, see Item 1A, “Risk Factors - A cybersecurity incident, data breach or a failure of key technology systems could adversely impact our business.”
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have a systematic and thorough risk management process, which is designed to identify, assess, prioritize and mitigate the risks that could negatively impact achievement of our strategic and operating objectives. A key component of this process is our Enterprise Risk Management (“ERM”) Committee, which is led by our Chairman, President and Chief Executive Officer, and includes our Chief Financial Officer, Chief Legal Officer, Chief Information Officer and other members of senior management.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors is focused on cybersecurity. Specific responsibility for cybersecurity oversight is delegated to the Audit Committee. The Board oversees our risk management process to ensure it is properly designed, well-functioning and consistent with our overall corporate strategy. Our Audit Committee oversees the ERM process and the implementation of appropriate risk monitoring and management systems, though all Board members attend Audit Committee meetings and participate in risk management discussions. Our Board of Directors has adopted a written statement, known as the Independent Board Candidate Qualifications and made available on our website, outlining the qualities sought in our directors. This statement, which is refreshed periodically, is used by the Nominating, Governance and Corporate Responsibility Committee (“NGCR Committee”) to evaluate individual director candidates. The NGCR Committee has identified experience with overseeing and managing risk management processes, including with respect to cybersecurity, as being important to creating an effective, well-rounded and diverse Board. Directors with experience overseeing and managing risk management processes play a critical role in the Board’s oversight of our enterprise risk management process. Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Specific responsibility for cybersecurity oversight is delegated to the Audit Committee.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.
Cybersecurity Risk Role of Management [Text Block]	We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats. Our Chief Information Officer reports to our Group President, Growth and Strategy, a member of our senior leadership team who reports to our Chairman of the Board, President and Chief Executive Officer. Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company’s systems and information. Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our CISO reports to the Audit Committee on cybersecurity quarterly, or more frequently if circumstances warrant, including relevant cybersecurity incidents impacting the Company and on topics related to information security, data privacy and cyber risks and mitigation strategies. In addition, outside experts periodically present to the Board on cybersecurity.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CISO has over 25 years of information technology experience, including leading data analytics, customer relationship management, architecture and application development teams. He has been leading our global information security program for almost seven years. He is a Certified Information Systems Professional, a member of Google Cloud CISO Customer Advisory Board and New Jersey Infragard and completed the FBI CISO Academy. He joined the Company over 25 years ago and has extensive knowledge regarding our business processes and the associated information technology platforms utilized worldwide, enabling him to guide his organization to protect the Company’s systems and information. Our Chief Information Officer joined the Company over 25 years ago and has expertise across a wide array of information technology and systems, with experience leading a large array of different functions within the global information technology organization. He has led our information technology Operational Performance and Reliability Committee for the last nine years, which reviews and provides continuous improvement processes and technology across infrastructure, information security, architecture, application and end user performance. He has application development leadership experience across all functions, including the policies and controls that govern both application development and implementation of packaged software. He has a certification from Stanford University for Cybersecurity and Executive Strategy.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	We have a dedicated information security organization, led by our CISO and overseen by our Chief Information Officer, which is responsible for assessing and managing material risks from cybersecurity threats.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Company’s assumptions and estimates involved in preparing the financial statements includes pension and other retiree benefit cost assumptions, stock-based compensation, asset impairments, uncertain tax positions, tax valuation allowances and legal and other contingency reserves. Additionally, the Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments and retirement plan assets. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. Actual results could ultimately differ from those estimates.
Revenue Recognition	Revenue Recognition The Company’s revenue contracts represent a single performance obligation to sell its products to trade customers. Sales are recorded at the time control of the products is transferred to trade customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the products. Control is the ability of trade customers to “direct the use of” and “obtain the benefit from” our products. In evaluating the timing of the transfer of control of products to trade customers, the Company considers several control indicators, including significant risks and rewards of products, the Company’s right to payment and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to trade customers. Net sales reflect the transaction prices for contracts, which include units shipped at selling list prices reduced by variable consideration. Variable consideration includes expected sales returns and the cost of current and continuing promotional programs. Current promotional programs primarily include product listing allowances and co-operative advertising arrangements. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements. The cost of promotional programs is estimated using the expected value method considering all reasonably available information, including the Company’s historical experience and its current expectations, and is reflected in the transaction price when sales are recorded. Adjustments to the cost of promotional programs in subsequent periods are generally not material, as the Company’s promotional programs are typically of short duration, thereby reducing the uncertainty inherent in such estimates. Sales returns are generally accepted at the Company’s discretion and are not material to the Company’s Consolidated Financial Statements. The Company’s contracts with trade customers do not have significant financing components or non-cash consideration and the Company does not have unbilled revenue or significant amounts of prepayments from customers. The Company records Net sales excluding taxes collected on its sales to its trade customers. Shipping and handling activities are accounted for as contract fulfillment costs and classified as Selling, general and administrative expenses.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs (also referred to as logistics costs) are classified as Selling, general and administrative expenses and were $1,777, $1,771 and $1,874 for the years ended December 31, 2024, 2023 and 2022, respectively.
Marketing Costs	Marketing Costs The Company markets its products through advertising and other promotional activities. Advertising costs are included in Selling, general and administrative expenses and are expensed as incurred. Certain consumer and trade promotional programs, such as consumer coupons, are recorded as a reduction of sales.
Cash and Cash equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
Inventories	Inventories The cost of approximately 75% of inventories is determined using the FIFO method, which is stated at the lower of cost or net realizable value. The cost of the remaining inventories, in the U.S. and Mexico, is determined using the LIFO method, which is stated at the lower of cost or market. Inventories in excess of one year of forecasted sales are classified in the Consolidated Balance Sheets as non-current “Other assets.”
Property, Plant and Equipment	Property, Plant and Equipment Land, buildings and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over the estimated useful lives ranging from 3 to 15 years for machinery and equipment and up to 40 years for buildings. Depreciation attributable to manufacturing operations is included in Cost of sales. The remaining component of depreciation is included in Selling, general and administrative expenses.
Goodwill and Other Intangibles	Goodwill and Other Intangibles Goodwill and indefinite-life intangible assets, such as the Company’s global brands, are subject to impairment tests at least annually or when events or changes in circumstances indicate that an asset may be impaired. In assessing impairment, the Company performs either a quantitative or a qualitative analysis. Determining the fair value of the Company’s reporting units for goodwill and the fair value of its intangible assets requires significant estimates and judgments by management. When a quantitative analysis is performed, the Company generally uses the income approach, which requires several estimates, including future cash flows consistent with management’s strategic plans, sales growth rates and the selection of royalty rates and discount rates. The Company generally engages a third-party valuation firm to assist in determining the fair value of intangible assets acquired in business combinations. As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reporting structure realignment, the Company completed an assessment indicating no goodwill impairment was required. Refer to Note 13, Segment Information for additional information. Other intangible assets with finite lives, such as local brands and trademarks, customer relationships and non-compete agreements, are amortized over their estimated useful lives, generally ranging from 5 to 40 years. Amortization expense related to intangible assets is included in Other (income) expense, net, which is included in Operating profit.
Income Taxes	Income Taxes The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company uses a comprehensive model to recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on an income tax return. The Company recognizes interest expense and penalties related to unrecognized tax benefits within Provision for income taxes.
Financial Instruments	Financial Instruments Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Company’s derivative instruments that qualify for hedge accounting are designated as either fair value hedges, cash flow hedges or net investment hedges. For fair value hedges, changes in the fair value of the derivative, as well as the offsetting changes in the fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings. For hedges of the net investment in foreign subsidiaries, changes in the fair value of the derivative are recorded in Other comprehensive income (loss) to offset the change in the value of the net investment being hedged. Cash flows related to hedges are classified in the same category as the cash flows from the hedged item in the Consolidated Statements of Cash Flows. The Company may also enter into certain foreign currency and interest rate instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period. The Company’s derivative instruments and other financial instruments are more fully described in Note 6, Fair Value Measurements and Financial Instruments along with the related fair value measurement considerations.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options and restricted stock units (both performance-based and time-vested), based on the fair value of those awards at the date of grant over the requisite service period. The Company uses the Black-Scholes-Merton ( “ Black-Scholes ” ) option pricing model to estimate the fair value of stock option awards. In addition to performance conditions, performance-based restricted stock units also include a total shareholder return modifier. Because the total shareholder return modifier is considered a market condition, the Company uses a Monte-Carlo simulation model to determine the fair value of performance-based restricted stock units. The fair value of time-vested restricted stock units is determined based on the closing market price of the Company’s stock at the date of grant. Stock-based compensation plans, related expenses and assumptions used in the Black-Scholes option pricing model are more fully described in Note 7, Capital Stock and Stock-Based Compensation Plans.
Currency Translation	Currency Translation The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. dollars at year-end exchange rates with resulting translation gains and losses accumulated in a separate component of shareholders’ equity. Income and expense items are translated into U.S. dollars at average rates of exchange prevailing during the year.
Recent Accounting Pronouncements	Recent Accounting Pronouncements and Disclosure Rules In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2024-04, “Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments.” This ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. This guidance is effective for the Company for fiscal years beginning after December 15, 2025 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires additional disclosures related to the disaggregation of income statement expense categories. This guidance is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In March 2024, the SEC finalized rules intended to enhance and standardize climate-related disclosures in registrants’ registration statements and Annual Reports on Form 10-K. The new rules would require climate-related disclosures, including as they relate to governance, strategy, risk management, targets and goals and greenhouse gas emissions. In addition, the rules would require certain climate-related disclosures as it relates to severe weather events and other natural conditions and carbon offsets and renewable energy credits. In April 2024, the SEC voluntarily stayed the rules due to pending judicial review. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for fiscal years beginning after December 15, 2024. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-08, “Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets.” This ASU improves the accounting for certain crypto assets by requiring companies to measure them at fair value for each reporting period with changes in fair value recognized in net income. This guidance is effective for the Company for fiscal years beginning after December 15, 2024 and is not expected to have an impact on the Company’s Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and other segment items. The Company adopted this guidance in 2024. See Note 13, Segment Information for additional information. In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” This ASU modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations. This guidance is effective for the Company no later than June 30, 2027. Other than the new disclosure requirements, this guidance will not have an impact on the Company’s Consolidated Financial Statements. In August 2023, the FASB issued ASU No. 2023-05, “Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement.” This ASU requires a joint venture to initially measure all contributions received upon its formation at fair value. This guidance is applicable to joint ventures with a formation date on or after January 1, 2025 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. In March 2023, the FASB issued ASU No. 2023-01, “Leases (Topic 842): Common Control Arrangements.” This ASU clarified the accounting for leasehold improvements for leases under common control. The guidance was effective for the Company beginning on January 1, 2024 and did not have a material impact on the Company’s Consolidated Financial Statements.
Reclassifications	Reclassifications

Nature of Operations (Tables)

Nature of Operations (Tables)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of Worldwide Sales	The Company’s principal classes of products accounted for the following percentages of worldwide Net sales for the past three years: 2024 2023 2022 Oral Care 43 % 42 % 43 % Personal Care 18 % 19 % 19 % Home Care 17 % 17 % 17 % Pet Nutrition 22 % 22 % 21 % Total 100 % 100 % 100 %

Restructuring and Related Imp_2

Restructuring and Related Implementation Charges (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	Over the course of the 2022 Global Productivity Initiative, the Company incurred total pretax charges of $228 ($186 aftertax) in connection with the implementation of various projects as follows: Total Program Charges as of December 31, 2024 Employee-Related Costs $ 175 Incremental Depreciation 13 Asset Impairments 1 Other 39 Total $ 228 For the twelve months ended December 31, 2024 and December 31, 2023, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows: Twelve Months Ended December 31, 2024 2023 Gross Profit $ 20 $ 1 Selling, general and administrative expenses 6 2 Other (income) expense, net 59 24 Non-service related postretirement costs — 5 Total 2022 Global Productivity Initiative charges, pretax $ 85 $ 32 Total 2022 Global Productivity Initiative charges, aftertax $ 73 $ 25 The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals: Twelve Months Ended December 31, Employee-Related Incremental Asset Other Total Balance at December 31, 2022 $ 30 $ — $ 1 $ 3 $ 34 Charges 24 — — 8 32 Cash Payments (45) — — (10) (55) Charges against assets (5) — (1) — (6) Foreign exchange 6 — — — 6 Balance at December 31, 2023 $ 10 $ — $ — $ 1 $ 11 Charges 49 13 — 23 85 Cash Payments (20) — — (14) (34) Charges against assets — (13) — — (13) Foreign exchange (5) — — — (5) Balance at December 31, 2024 $ 34 $ — $ — $ 10 $ 44
Schedule of Percent of Total Restructuring Charges Related To Segment for the period	Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments: Twelve Months Ended December 31, Total Program Charges 2024 2023 North America (1) 3 % 15 % 9 % Latin America — % — % 9 % Europe (1) 89 % 19 % 44 % Asia Pacific — % 20 % 7 % Africa/Eurasia — % 5 % 6 % Hill's Pet Nutrition 6 % 23 % 11 % Corporate 2 % 18 % 14 % Total 100 % 100 % 100 % (1) The Company has recast its historical geographic segment information to conform to the reporting structure effective as of July 1, 2024. See Note 13, Segment Information for additional details.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Segment	The changes in net carrying value of Goodwill by segment for the years ended December 31, 2024 and 2023 were as follows: 2023 Beginning Balance Foreign currency translation Ending Balance Oral, Personal and Home Care North America $ 906 $ 2 $ 908 Latin America 168 11 179 Europe 1,504 67 1,571 Asia Pacific 179 — 179 Africa/Eurasia 107 (19) 88 Total Oral, Personal and Home Care 2,864 61 2,925 Pet Nutrition 488 (3) 485 Total Goodwill $ 3,352 $ 58 $ 3,410 2024 Beginning Balance Reallocation (1) Foreign currency translation Ending Balance Oral, Personal and Home Care North America $ 908 $ 223 $ (23) $ 1,108 Latin America 179 — (34) 145 Europe 1,571 (223) (67) 1,281 Asia Pacific 179 — (1) 178 Africa/Eurasia 88 — (10) 78 Total Oral, Personal and Home Care 2,925 — (135) 2,790 Pet Nutrition 485 — (3) 482 Total Goodwill $ 3,410 $ — $ (138) $ 3,272 (1) As a result of a reporting structure realignment, the Company reallocated the goodwill of a certain reporting unit from the Europe segment to the North America segment. Before and after the reallocation of the goodwill, the Company completed an assessment indicating no goodwill impairment was required as a result of this segment reporting structure realignment. Refer to Note 13, Segment Information for additional information.
Schedule of Finite and Indefinite Lived Intangible Assets By Major Class	Other intangible assets as of December 31, 2024 and 2023 were comprised of the following: 2024 2023 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trademarks - finite life $ 1,135 $ (545) $ 590 $ 1,167 $ (519) $ 648 Other finite life intangible assets 603 (385) 218 624 (363) 261 Indefinite life intangible assets 948 — 948 978 — 978 Total Other intangible assets $ 2,686 $ (930) $ 1,756 $ 2,769 $ (882) $ 1,887

Long-Term Debt and Credit Fac_2

Long-Term Debt and Credit Facilities (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt consisted of the following at December 31: Weighted Average Interest Rate Maturities 2024 2023 Notes 3.0% 2025 - 2078 $ 6,946 $ 7,580 Commercial paper 3.0% 2025 936 606 Finance Lease Obligations Various 59 53 7,941 8,239 Less: Current portion of long-term debt (652) (20) Total $ 7,289 $ 8,219
Schedule of Short-Term Debt	Debt payable within one year consisted of the following at December 31: 2024 2023 Notes and loans payable $ 8 $ 310 Current portion of long-term debt 652 20 Debt payable within one year $ 660 $ 330
Schedule of Maturities of Long-term Debt	Excluding commercial paper, scheduled maturities of long-term debt and finance leases outstanding as of December 31, 2024, were as follows: Years Ended December 31, 2025 $ 652 2026 1,035 2027 509 2028 612 2029 519 Thereafter 3,678 Total $ 7,005

Fair Value Measurements and F_2

Fair Value Measurements and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Derivative Instruments	The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets as of December 31, 2024 and 2023: Assets Liabilities Account Fair Value Account Fair Value Designated derivative instruments December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Foreign currency contracts Other current assets 33 19 Other accruals 22 25 Commodity contracts Other current assets — — Other accruals 1 1 Total designated $ 33 $ 19 $ 23 $ 26 Other financial instruments Marketable securities Other current assets 160 179 Total other financial instruments $ 160 $ 179
Schedule of Notional Amounts of Outstanding Derivative Positions	The following tables present the notional values as of: December 31, 2024 Foreign Foreign Currency Debt Commodity Contracts Fair Value Hedges $ 1,669 $ — $ — $ 1,669 Cash Flow Hedges 1,023 — 18 1,041 Net Investment Hedges 289 3,750 — 4,039 December 31, 2023 Foreign Foreign Currency Debt Commodity Contracts Fair Value Hedges $ 1,625 $ — $ — $ 1,625 Cash Flow Hedges 869 — 39 908 Net Investment Hedges 280 3,908 — 4,188
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	The following table presents the amount of gain (loss) on net investment hedges recognized in the Company’s AOCI: Gain (Loss) Recognized in AOCI Twelve Months Ended December 31, Hedging instruments: 2024 2023 Foreign currency contracts $ 42 $ (34) Foreign currency debt 211 (124) Total gain (loss) on net investment hedges $ 253 $ (158)

Capital Stock and Stock-Based_2

Capital Stock and Stock-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Common and Treasury Stock Activity	A summary of common stock and treasury stock activity for the three years ended December 31 is as follows: Common Stock Outstanding Treasury Stock Balance, January 1, 2022 840,480,284 625,226,076 Common stock acquired (17,060,788) 17,060,788 Shares issued for stock options 5,654,692 (5,654,692) Shares issued for restricted stock units and other 1,138,418 (1,138,418) Balance, December 31, 2022 830,212,606 635,493,754 Common stock acquired (14,735,909) 14,735,909 Shares issued for stock options 5,318,430 (5,318,430) Shares issued for restricted stock units and other 617,642 (617,642) Balance, December 31, 2023 821,412,769 644,293,591 Common stock acquired (18,321,422) 18,321,422 Shares issued for stock options 8,606,699 (8,606,699) Shares issued for restricted stock units and other 876,652 (876,652) Balance, December 31, 2024 812,574,698 653,131,662
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	The weighted-average fair value assumptions are summarized in the following table: 2024 2023 2022 Expected term of options 6 years 6 years 6 years Expected volatility rate 20.5 % 19.8 % 21.1 % Risk-free interest rate 3.8 % 4.3 % 3.0 % Expected dividend yield 2.1 % 2.5 % 2.4 % Weighted-average estimated fair value $ 22.65 $ 14.89 $ 14.71
Schedule of Share-based Compensation, Stock Options, Activity	A summary of stock option activity during 2024 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Intrinsic Value of Unexercised Options outstanding, January 1, 2024 20,742 $ 75 Granted 955 106 Exercised (8,662) 74 Forfeited (240) 76 Expired (21) 73 Options outstanding, December 31, 2024 12,774 78 5 $ 176 Options exercisable, December 31, 2024 9,265 $ 76 4 $ 136
Schedule of Share-based Compensation, Performance Restricted Stock and Time-based Restricted Stock Units Activity	A summary of performance-based restricted stock unit activity for the year ended December 31, 2024 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Performance-based restricted stock units as of January 1, 2024 1,069 $ 68 Activity: Granted 321 91 Vested (283) 70 Forfeited (89) 72 Change due to performance and/or market condition achievement 19 57 Performance-based restricted stock units as of December 31, 2024 1,037 $ 74 A summary of restricted stock unit activity during 2024 is presented below: Shares Weighted Average Grant Date Fair Value Per Award Restricted stock units as of January 1, 2024 2,174 $ 76 Activity: Granted 854 105 Vested (951) 76 Forfeited (90) 77 Restricted stock units as of December 31, 2024 1,987 $ 88

Retirement Plans and Other Re_2

Retirement Plans and Other Retiree Benefits (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Schedule of Allocation of Plan Assets	The target asset allocation for the Company’s defined benefit plans is as follows: United States International Asset Category Equity securities 26 % 17 % Fixed income securities 60 % 63 % Other investments 14 % 20 % Total 100 % 100 % At December 31, 2024, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Cash and cash equivalents Level 1 $ 226 $ 21 U.S. common stocks Level 1 1 2 International common stocks Level 1 — 15 Pooled funds (1) Level 1 35 103 Fixed income securities (2) Level 2 624 75 Guaranteed investment contracts (3) Level 2 — 30 886 246 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 223 28 Fixed income funds (5) 68 222 Hedge funds (6) — 7 Multi-asset funds (7) 157 2 Real estate funds (8) — 27 448 286 Other assets and liabilities, net (9) (39) 5 Total Investments $ 1,295 $ 537 At December 31, 2023, the allocation of the Company’s plan assets and the level of valuation input, as applicable, for each major asset category were as follows: Level of Valuation Pension Plans United States International Cash and cash equivalents Level 1 $ 206 $ 14 U.S. common stocks Level 1 — 2 International common stocks Level 1 — 20 Pooled funds (1) Level 1 20 113 Fixed income securities (2) Level 2 710 71 Guaranteed investment contracts (3) Level 2 — 34 936 254 Investments valued using NAV per share (4) Domestic, developed and emerging markets equity funds 315 55 Fixed income funds (5) 99 219 Hedge funds (6) — 7 Multi-asset funds (7) 40 1 Real estate funds (8) — 30 454 312 Other assets and liabilities, net (9) (30) — Total Investments $ 1,360 $ 566 (1) Pooled funds primarily invest in U.S. and foreign equity securities, debt and money market securities. (2) The fixed income securities are traded over-the-counter and certain of these securities lack daily pricing or liquidity and as such are classified as Level 2. As of December 31, 2024 and December 31, 2023, approximately 30% of the U.S. pension plan fixed income portfolio was invested in U.S. treasury or agency securities, with the remainder invested in other government bonds and corporate bonds. (3) The guaranteed investment contracts (“GICs”) represent contracts with insurance companies measured at the cash surrender value of each contract. The Level 2 valuation reflects that the cash surrender value is based principally on a referenced pool of investment funds with active redemption. (4) Investments that are measured at fair value using net asset value (“NAV”) per share as a practical expedient have not been classified in the fair value hierarchy. The NAV is based on the value of the underlying investments owned, minus its liabilities, divided by the number of shares outstanding. There are no unfunded commitments related to these investments. Redemption notice period primarily ranges from 0-3 months and redemption frequency windows range from daily to quarterly. (5) Fixed income funds primarily invest in U.S. government and investment grade corporate bonds. (6) Consists of investments in underlying hedge fund strategies that are primarily implemented through the use of long and short equity and fixed income securities and derivative instruments such as futures and options. (7) Multi-asset funds primarily invest across a variety of asset classes, including global stocks and bonds, as well as alternative strategies. (8) Real estate is valued using the NAV per unit of funds that are invested in real estate property. The investment value of the real estate property is determined quarterly using independent market appraisals as determined by the investment manager. (9)
Schedule of Defined Benefit Plans Disclosures	The Company uses a December 31 measurement date for its defined benefit and other retiree benefit plans. Summarized information for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2024 2023 2024 2023 2024 2023 United States International Change in Benefit Obligations Benefit obligations at beginning of year $ 1,922 $ 1,673 $ 776 $ 675 $ 665 $ 658 Service cost 1 — 16 15 7 7 Interest cost 99 91 33 33 36 38 Participants’ contributions — — 5 5 — — Plan amendments — — — — — (33) Actuarial loss (gain) (54) 36 (11) 65 (14) 38 Foreign exchange impact — — (40) 29 (8) 4 Termination benefits 5 3 — 2 — — Curtailments and settlements (1) — (18) (6) — — Benefit payments (141) (148) (41) (42) (54) (47) ERISA litigation matter — 267 — — — — Benefit obligations at end of year $ 1,831 $ 1,922 $ 720 $ 776 $ 632 $ 665 Change in Plan Assets Fair value of plan assets at beginning of year $ 1,360 $ 1,363 $ 566 $ 516 $ — $ — Actual return on plan assets 49 115 18 26 — — Company contributions 29 30 37 39 54 47 Participants’ contributions — — 5 5 — — Foreign exchange impact — — (31) 27 — — Settlements and acquisitions (2) — (17) (5) — — Benefit payments (141) (148) (41) (42) (54) (47) Fair value of plan assets at end of year $ 1,295 $ 1,360 $ 537 $ 566 $ — $ — Funded Status Benefit obligations at end of year $ 1,831 $ 1,922 $ 720 $ 776 $ 632 $ 665 Fair value of plan assets at end of year 1,295 1,360 537 566 — — Net amount recognized $ (536) $ (562) $ (183) $ (210) $ (632) $ (665) Amounts Recognized in Balance Sheet Noncurrent assets $ 1 $ 1 $ 47 $ 48 $ — $ — Current liabilities (27) (28) (15) (15) (51) (53) Noncurrent liabilities (510) (535) (215) (243) (581) (612) Net amount recognized $ (536) $ (562) $ (183) $ (210) $ (632) $ (665) Amounts Recognized in Accumulated Other Comprehensive Income (Loss) Actuarial loss $ 710 $ 767 $ 174 $ 177 $ 109 $ 128 Transition/prior service cost(credit) — — 8 9 (159) (180) $ 710 $ 767 $ 182 $ 186 $ (50) $ (52) Accumulated benefit obligation $ 1,818 $ 1,907 $ 668 $ 719 $ — $ — Pension Plans Other Retiree Benefit Plans 2024 2023 2024 2023 2024 2023 United States International Weighted-Average Assumptions Used to Determine Benefit Obligations Discount rate 5.73 % 5.40 % 4.69 % 4.35 % 5.74 % 5.37 % Long-term rate of compensation increase 3.50 % 3.50 % 3.36 % 3.19 % — % — % ESOP growth rate — % — % — % — % 6.00 % 6.00 % Medical cost trend rate of increase — % — % — % — % 7.00 % 6.00 % Interest Crediting Rate 5.58 % 4.99 % 3.23 % 1.13 % — % — %
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	Pension plans with projected benefit obligations in excess of plan assets and plans with accumulated benefit obligations in excess of plan assets as of December 31 consisted of the following: 2024 2023 Benefit Obligation Exceeds Fair Value of Plan Assets Projected benefit obligation $ 2,251 $ 2,352 Fair value of plan assets 1,486 1,532 Accumulated benefit obligation 2,075 2,204 Fair value of plan assets 1,345 1,428 Other Retiree Benefit plans with accumulated postretirement benefit obligation in excess of plan assets as of December 31 consisted of the following: 2024 2023 Benefit Obligation Exceeds Fair Value of Plan Assets Accumulated postretirement benefit obligation $ 632 $ 665 Fair value of plan assets — —
Schedule of Net Benefit Costs	Summarized information regarding the net periodic benefit costs for the Company’s defined benefit and other retiree benefit plans is as follows: Pension Plans Other Retiree Benefit Plans 2024 2023 2022 2024 2023 2022 2024 2023 2022 United States International Components of Net Periodic Benefit Cost Service cost $ 1 $ — $ — $ 16 $ 15 $ 15 $ 7 $ 7 $ 18 Interest cost 99 91 64 33 33 21 36 38 36 Expected return on plan assets (85) (79) (101) (29) (25) (21) — — — Amortization of transition and prior service costs (credits) — — — 1 1 1 (21) (20) (6) Amortization of actuarial loss 39 43 46 5 5 7 4 1 14 Net periodic benefit cost $ 54 $ 55 $ 9 $ 26 $ 29 $ 23 $ 26 $ 26 $ 62 Other postretirement charges 5 3 13 — 2 4 — — 2 ERISA litigation matter — 267 — — — — — — — Total pension cost $ 59 $ 325 $ 22 $ 26 $ 31 $ 27 $ 26 $ 26 $ 64 Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost Discount rate 5.40 % 5.66 % 2.98 % 4.61 % 4.75 % 2.10 % 5.37 % 5.67 % 3.06 % Expected long-term rate of return on plan assets 6.50 % 6.25 % 5.70 % 5.69 % 4.66 % 2.72 % N/A N/A N/A Long-term rate of compensation increase 3.50 % 3.50 % 3.50 % 3.24 % 3.22 % 2.89 % — % — % — % ESOP growth rate — % — % — % — % — % — % 6.00 % 6.00 % 6.00 % Medical cost trend rate of increase — % — % — % — % — % — % 6.00 % 6.25 % 6.00 % Interest Crediting Rate 4.99 % 5.21 % 2.82 % 0.64 % 2.28 % 0.84 % — % — % — %
Schedule of Expected Benefit Payments	Total benefit payments expected to be paid to participants in both funded and unfunded plans are estimated as follows: Pension Plans Years Ended December 31, United States International Other Retiree Benefit Plans Total 2025 $ 377 $ 42 $ 52 471 2026 143 41 54 238 2027 143 43 55 241 2028 142 45 55 242 2029 141 46 55 242 2030-2034 653 247 274 1,174

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Before Income Taxes	The components of Income before income taxes are as follows for the years ended December 31: 2024 2023 2022 United States $ 1,084 $ 692 $ 1,169 International 2,872 2,700 1,491 Total Income before income taxes $ 3,956 $ 3,392 $ 2,660
Schedule of Provision for Income Taxes	The Provision for income taxes consists of the following for the years ended December 31: 2024 2023 2022 United States $ 188 $ 72 $ 199 International 719 865 494 Total Provision for income taxes $ 907 $ 937 $ 693
Schedule of Components of Deferred Income Tax Benefit	Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in the current provision for taxes being higher (lower) than the total provision for income taxes as follows: 2024 2023 2022 Goodwill and intangible assets $ 3 $ 1 $ 106 Property, plant and equipment 12 (13) 2 Pension and other retiree benefits (6) 68 (1) Stock-based compensation (14) 2 (3) Right-of-use assets/lease liabilities 2 1 (5) Tax credits and tax loss carryforwards, net of valuation allowance 37 29 8 Deferred withholding tax (14) 7 8 Research and Experimentation Capitalization 21 29 58 Other, net (8) 11 (10) Total deferred tax benefit (provision) $ 33 $ 135 $ 163
Schedule of Effective Tax Rate Reconciliation	The difference between the statutory U.S. federal income tax rate and the Company’s global effective tax rate as reflected in the Consolidated Statements of Income is as follows: 2024 2023 2022 Percentage of Income before income taxes Tax at United States statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 0.5 (0.1) 0.8 Earnings taxed at other than United States statutory rate 4.1 5.4 5.4 Non-deductible goodwill impairment charges — — 1.9 Foreign-derived intangible income benefit (2.6) (2.4) (2.6) Foreign tax matter — 3.7 — Other, net (0.1) — (0.4) Effective tax rate 22.9 % 27.6 % 26.1 %
Schedule of Components of Deferred Tax Assets (Liabilities)	The components of deferred tax assets (liabilities) are as follows at December 31: 2024 2023 Deferred tax liabilities: Goodwill and intangible assets $ (389) $ (412) Property, plant and equipment (397) (420) Right-of-use assets (126) (126) Deferred withholding tax (110) (96) Other (130) (34) Total deferred tax liabilities (1,152) (1,088) Deferred tax assets: Pension and other retiree benefits 272 295 Tax credits and tax loss carryforwards 430 356 Lease liabilities 137 134 Accrued liabilities 223 221 Stock-based compensation 61 75 Research and Experimentation Capitalization 108 87 Other 101 60 Total deferred tax assets 1,332 1,228 Valuation Allowance $ (328) $ (287) Net deferred tax assets $ 1,004 $ 941 Net deferred income taxes $ (148) $ (147) The changes in valuation allowance for deferred tax assets are as follows: 2024 2023 2022 Balance, January 1 $ 287 $ 129 $ 120 Additions Charged to costs and expenses 56 158 14 Deductions 15 — 5 Balance, December 31 $ 328 $ 287 $ 129
Schedule of Unrecognized Tax Benefits Activity	Unrecognized tax benefits activity for the years ended December 31, 2024, 2023 and 2022 is summarized below: 2024 2023 2022 Unrecognized tax benefits: Balance, January 1 $ 314 $ 298 $ 245 Increases as a result of tax positions taken during the current year 37 73 32 Decreases of tax positions taken during prior years (53) (61) (21) Increases of tax positions taken during prior years 10 6 46 Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations (3) (2) (2) Effect of foreign currency rate movements (9) — (2) Balance, December 31 $ 296 $ 314 $ 298

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	For the years ended December 31, 2024, 2023 and 2022, earnings per share were as follows: 2024 2023 2022 Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Net income attributable to Colgate-Palmolive Company Shares Per Basic EPS $ 2,889 819.1 $ 3.53 $ 2,300 827.4 $ 2.78 $ 1,785 836.4 $ 2.13 Stock options and restricted stock units 4.1 1.8 2.4 Diluted EPS $ 2,889 823.2 $ 3.51 $ 2,300 829.2 $ 2.77 $ 1,785 838.8 $ 2.13

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Net Sales and Operating Profit by Segment	2024 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,113 $ 1,571 $ 1,668 $ 36 $ 839 Latin America 4,782 1,933 1,328 (5) 1,526 Europe 2,770 1,050 1,031 31 658 Asia Pacific 2,858 1,078 997 (30) 812 Africa/Eurasia 1,095 432 395 16 253 Total Oral, Personal and Home Care 15,618 4,088 Pet Nutrition (2) 4,483 1,869 1,641 8 965 Reconciliation with Total Company Operating Profit Corporate (784) Total $ 20,101 $ 4,268 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,640 in 2024. (2) Net sales in the U.S. for Pet Nutrition were $3,059 in 2024. (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2023 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,091 $ 1,588 $ 1,594 $ 37 $ 871 Latin America 4,640 1,977 1,241 5 1,417 Europe 2,571 1,069 899 31 573 Asia Pacific 2,782 1,108 925 (18) 767 Africa/Eurasia 1,083 442 377 9 254 Total Oral, Personal and Home Care 15,167 3,882 Pet Nutrition (2) 4,290 1,964 1,493 26 806 Reconciliation with Total Company Operating Profit Corporate $ (704) Total $ 19,457 $ 3,984 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,625 in 2023. (2) Net sales in the U.S. for Pet Nutrition were $2,918 in 2023. (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2022 Net sales Cost of Sales Selling, general and administrative expenses Other (income) expense, net (3) Operating Profit Reportable Segments Oral, Personal and Home Care North America (1) $ 4,002 $ 1,649 $ 1,567 $ 46 $ 741 Latin America 3,982 1,885 1,059 (71) 1,108 Europe 2,362 1,023 778 28 534 Asia Pacific 2,826 1,160 954 (24) 737 Africa/Eurasia 1,082 447 389 18 228 Total Oral, Personal and Home Care 14,254 3,348 Pet Nutrition (2) 3,713 1,569 1,287 7 850 Reconciliation with Total Company Operating Profit Corporate $ (1,305) Total $ 17,967 $ 2,893 Note: Table may not sum due to rounding. (1) Net sales in the U.S. for Oral, Personal and Home Care were $3,511 in 2022. (2) Net sales in the U.S. for Pet Nutrition were $2,432 in 2022 (3) Refer to Note 16, Supplemental Income Statement for information related to Other (income) expense, net. 2024 2023 2022 Capital expenditures Oral, Personal and Home Care North America $ 52 $ 46 $ 66 Latin America 126 146 121 Europe 63 44 31 Asia Pacific 64 65 60 Africa/Eurasia 12 10 30 Total Oral, Personal and Home Care 317 311 308 Pet Nutrition 143 301 297 Corporate 101 93 91 Total Capital expenditures $ 561 $ 705 $ 696 2024 2023 2022 Depreciation and amortization Oral, Personal and Home Care North America $ 124 $ 116 $ 128 Latin America 100 98 93 Europe 65 65 68 Asia Pacific 81 84 89 Africa/Eurasia 8 9 9 Total Oral, Personal and Home Care 378 372 387 Pet Nutrition 132 101 65 Corporate 95 94 93 Total Depreciation and amortization $ 605 $ 567 $ 545 2024 2023 Long-lived assets (1) United States $ 2,728 $ 2,733 International 2,223 2,340 Total Long-lived assets $ 4,951 $ 5,073 (1)

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Right-of-use Assets and Liabilities for Operating Leases	As of December 31, 2024 and 2023, the Company’s right-of use assets and liabilities for operating leases were as follows: 2024 2023 Other assets $ 529 $ 491 Other accruals 107 95 Other liabilities 456 420 Total operating lease liabilities $ 563 $ 515
Schedule of Operating Lease Liabilities	Lease liabilities for operating leases as of December 31, 2024 were as follows: 2025 $ 126 2026 108 2027 101 2028 80 2029 58 Thereafter 182 Total lease commitments $ 655 Less: Interest (92) Present value of lease liabilities $ 563
Schedule of Components of Operating Lease Expense	The components of the Company’s operating lease cost for the twelve months ended December 31, 2024 and 2023 were as follows: 2024 2023 Operating lease cost $ 144 $ 136 Short-term lease cost 3 3 Variable lease cost 19 20 Sublease Income (2) (2) Total lease cost $ 164 $ 157

Supplemental Income Statement_2

Supplemental Income Statement Information (Tables)	12 Months Ended
	Dec. 31, 2024
Supplemental Income Statement Elements [Abstract]
Other (income) expense, net	Other (income) expense, net 2024 2023 2022 Amortization of intangible assets $ 75 $ 72 $ 80 Equity income (22) (17) (12) 2022 Global Productivity Initiative 59 24 90 Product recall costs — 25 — Losses (gains) from marketable securities and other assets 6 11 (22) Indirect tax payments (refunds) 27 18 (14) Gain on the sale of land in Asia Pacific — — (47) Acquisition-related costs — — 19 Other, net 19 58 (25) Total Other (income) expense, net $ 164 $ 191 $ 69
Research and development and Advertising	2024 2023 2022 Research and development $ 355 $ 343 $ 320 Advertising $ 2,720 $ 2,371 $ 1,997

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventories by Major Class	Inventories by major class are as follows at December 31: Inventories 2024 2023 Raw materials and supplies $ 631 $ 606 Work-in-process 46 46 Finished goods 1,431 1,411 Total Inventories, net $ 2,108 $ 2,063 Non-current inventory, net (121) (129) Current Inventories, net $ 1,987 $ 1,934
Schedule of Property, Plant and Equipment	Property, plant and equipment, net 2024 2023 Land $ 226 $ 227 Buildings 2,056 2,047 Manufacturing machinery and equipment 6,265 6,365 Other equipment 1,580 1,647 10,127 10,286 Accumulated depreciation (5,705) (5,704) Total Property, plant and equipment, net $ 4,422 $ 4,582
Schedule of Other Current Assets	Other current assets 2024 2023 Marketable securities $ 160 $ 179 Prepaids 520 595 Derivatives 33 19 Total Other current assets $ 713 $ 793
Schedule of Other Accruals	Other accruals 2024 2023 Accrued advertising and consumer and trade promotions $ 912 $ 882 Accrued payroll and employee benefits 437 403 Accrued taxes other than income taxes 162 167 Restructuring accrual 15 11 Pension and other retiree benefits 93 96 Lease liabilities due in one year 107 95 Accrued interest 72 78 Derivatives 23 26 Dividend payable 408 — Other 662 619 Total Other accruals $ 2,891 $ 2,377
Schedule of Other Liabilities	Other liabilities 2024 2023 Pension and other retiree benefits $ 1,306 $ 1,390 Long-term lease liabilities 456 420 Restructuring accrual 29 — Other 320 305 Total Other liabilities $ 2,111 $ 2,115

Supplemental Other Comprehens_2

Supplemental Other Comprehensive Income (Loss) Information (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Comprehensive Income (Loss)	Other comprehensive income (loss) components attributable to Colgate-Palmolive Company before tax and net of tax during the years ended December 31 were as follows: 2024 2023 2022 Cumulative translation adjustments: Cumulative translation adjustments, pre-tax $ (298) $ 127 $ (113) Tax amounts (37) 13 (29) Cumulative translation adjustments, net of tax (335) 140 (142) Pension and other benefits: Net actuarial gain (loss), prior service costs and settlements 31 (49) 466 Amortization of net actuarial loss, transition and prior service costs (1) 28 30 62 Retirement Plan and other retiree benefit adjustments, pre-tax 59 (19) 528 Tax amounts (16) 3 (115) Retirement Plan and other retiree benefit adjustments, net of tax 43 (16) 413 Cash flow hedges: Gains (losses) on cash flow hedges, pre-tax 10 (10) 80 Tax amounts (2) 3 (20) Gains (losses) on cash flow hedges, net of tax 8 (7) 60 Total Other comprehensive income (loss), net of tax $ (284) $ 117 $ 331 (1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.

Nature of Operations (Details)

Nature of Operations (Details) - Sales Revenue, Net - Product Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Oral Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	43%	42%	43%
Personal Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	18%	19%	19%
Home Care
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	17%	17%	17%
Pet Nutrition
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	22%	22%	21%
Product
Entity-Wide Information, Revenue from External Customer [Line Items]
Percent of net sales	100%	100%	100%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Principles of Consolidation, Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Investments accounted for using the equity method, minimum interest	20%
Investments accounted for using the equity method, maximum interest	50%
Equity method investments included in other assets	$ 81	$ 83
Investments accounted for using the cost method, maximum interest	20%
Approximate percentage of inventories determined using the first-in, first-out (FIFO) method	75%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Shipping and Handling Costs, Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Selling, general and administrative expenses	$ 7,729	$ 7,151	$ 6,565
Minimum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Shipping and Handling
Property, Plant and Equipment [Line Items]
Selling, general and administrative expenses	$ 1,777	$ 1,771	$ 1,874

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Goodwill and Other Intangibles (Details) - Local Brands, Trademarks, Customer Relationships, and Non-Compete Agreements	Dec. 31, 2024
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangible assets	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of finite-lived intangible assets	40 years

Restructuring and Related Imp_3

Restructuring and Related Implementation Charges - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Jan. 27, 2022
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	$ 228
Restructuring and related cost incurred cost to date after tax	$ 186
Global Productivity Initiative | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage		80%
Global Productivity Initiative | Asset Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage		5%
Global Productivity Initiative | Other Charges
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost, percentage		15%
Global Productivity Initiative | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and related Cost, estimated to settle through cash, percentage		80%

Restructuring and Related Imp_4

Restructuring and Related Implementation Charges - Summary of Restructuring Charges, Cumulative to Date (Details) $ in Millions	Dec. 31, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	$ 228
Global Growth and Efficiency Program
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	228
Global Growth and Efficiency Program | Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	175
Global Growth and Efficiency Program | Incremental Depreciation
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	13
Global Growth and Efficiency Program | Asset Impairments
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	1
Global Growth and Efficiency Program | Other
Restructuring Cost and Reserve [Line Items]
Pretax charges related to the Restructuring Program to date	$ 39

Restructuring and Related Imp_5

Restructuring and Related Implementation Charges - Summary of Restructuring and Related Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Total 2022 Global Productivity Initiative charges, pretax	$ 20	$ 1
Global Productivity Initiative
Restructuring Cost and Reserve [Line Items]
Total 2022 Global Productivity Initiative charges, pretax	85	32	$ 95
Total 2022 Global Productivity Initiative charges, aftertax	73	25
Global Productivity Initiative | Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total 2022 Global Productivity Initiative charges, pretax	$ 6	$ 2
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses
Global Productivity Initiative | Other (income) expense, net
Restructuring Cost and Reserve [Line Items]
Total 2022 Global Productivity Initiative charges, pretax	$ 59	$ 24
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Operating Income (Expense), Net	Other Operating Income (Expense), Net
Global Productivity Initiative | Non-service related postretirement costs
Restructuring Cost and Reserve [Line Items]
Total 2022 Global Productivity Initiative charges, pretax	$ 0	$ 5
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Non-service related postretirement costs	Non-service related postretirement costs

Restructuring and Related Imp_6

Restructuring and Related Implementation Charges - Restructuring Charges Incurred, by Segment (Details) - Global Productivity Initiative	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	100%	100%
Program-to-date accumulated charges (percent)	100%
Pet Nutrition
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	6%	23%
Program-to-date accumulated charges (percent)	11%
Corporate
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	2%	18%
Program-to-date accumulated charges (percent)	14%
North America
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	3%	15%
Program-to-date accumulated charges (percent)	9%
Latin America
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	0%	0%
Program-to-date accumulated charges (percent)	9%
Europe
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	89%	19%
Program-to-date accumulated charges (percent)	44%
Asia Pacific
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	0%	20%
Program-to-date accumulated charges (percent)	7%
Africa/Eurasia
Restructuring Cost and Reserve [Line Items]
Percent of total restructuring charges related to segment	0%	5%
Program-to-date accumulated charges (percent)	6%

Restructuring and Related Imp_7

Restructuring and Related Implementation Charges - Restructuring Activity and Related Accruals (Details) - Global Productivity Initiative - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]
Beginning balance	$ 11	$ 34
Charges	85	32
Cash Payments	(34)	(55)
Charges against assets	(13)	(6)
Foreign exchange	(5)	6
Ending balance	44	11
Employee-Related Costs
Restructuring Reserve [Roll Forward]
Beginning balance	10	30
Charges	49	24
Cash Payments	(20)	(45)
Charges against assets	0	(5)
Foreign exchange	(5)	6
Ending balance	34	10
Incremental Depreciation
Restructuring Reserve [Roll Forward]
Beginning balance	0	0
Charges	13	0
Cash Payments	0	0
Charges against assets	(13)	0
Foreign exchange	0	0
Ending balance	0	0
Asset Impairments
Restructuring Reserve [Roll Forward]
Beginning balance	0	1
Charges	0	0
Cash Payments	0	0
Charges against assets	0	(1)
Foreign exchange	0	0
Ending balance	0	0
Other
Restructuring Reserve [Roll Forward]
Beginning balance	1	3
Charges	23	8
Cash Payments	(14)	(10)
Charges against assets	0	0
Foreign exchange	0	0
Ending balance	$ 10	$ 1

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning Balance	$ 3,410	$ 3,352
Reallocation	0
Foreign currency translation	(138)	58
Ending Balance	3,272	3,410
Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	2,925	2,864
Reallocation	0
Foreign currency translation	(135)	61
Ending Balance	2,790	2,925
Pet Nutrition
Goodwill [Roll Forward]
Beginning Balance	485	488
Foreign currency translation	(3)	(3)
Ending Balance	482	485
North America | Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	908	906
Reallocation	223
Foreign currency translation	(23)	2
Ending Balance	1,108	908
Latin America | Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	179	168
Foreign currency translation	(34)	11
Ending Balance	145	179
Europe | Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	1,571	1,504
Reallocation	(223)
Foreign currency translation	(67)	67
Ending Balance	1,281	1,571
Asia Pacific | Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	179	179
Foreign currency translation	(1)	0
Ending Balance	178	179
Africa/Eurasia | Oral, Personal and Home Care
Goodwill [Roll Forward]
Beginning Balance	88	107
Foreign currency translation	(10)	(19)
Ending Balance	$ 78	$ 88

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Finite and indefinite-lived intangible assets [Line Items]
Finite & indefinite lived intangibles, gross	$ 2,686	$ 2,769
Finite-lived intangible assets, accumulated amortization	(930)	(882)
Intangible assets, net (excluding goodwill)	1,756	1,887
Indefinite life intangible assets
Finite and indefinite-lived intangible assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	948	978
Trademarks
Finite and indefinite-lived intangible assets [Line Items]
Finite-lived intangible assets, gross	1,135	1,167
Finite-lived intangible assets, accumulated amortization	(545)	(519)
Finite-lived intangible assets, net	590	648
Other finite life intangible assets
Finite and indefinite-lived intangible assets [Line Items]
Finite-lived intangible assets, gross	603	624
Finite-lived intangible assets, accumulated amortization	(385)	(363)
Finite-lived intangible assets, net	$ 218	$ 261

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Amortization of intangible assets	$ 75	$ 72	$ 80
Annual estimated amortization expense, year 1	68
Annual estimated amortization expense, year 2	68
Annual estimated amortization expense, year 3	68
Annual estimated amortization expense, year 4	68
Annual estimated amortization expense, year 5	68
Indefinite life intangible assets
Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	948	$ 978
Trademarks
Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 234
Estimated remaining useful life (in years)	24 years
Filorga Reporting Unit | Trademarks
Goodwill [Line Items]
Reporting unit, impairment analysis carrying amount	$ 293

Long-Term Debt and Credit Fac_3

Long-Term Debt and Credit Facilities - Components of Long-term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt	$ 7,941	$ 8,239
Less: Current portion of long-term debt	(652)	(20)
Total	$ 7,289	8,219
Notes
Debt Instrument [Line Items]
Weighted average interest rate	3%
Total debt	$ 6,946	7,580
Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate	3%
Total debt	$ 936	606
Finance Lease Obligations
Debt Instrument [Line Items]
Total debt	$ 59	$ 53

Long-Term Debt and Credit Fac_4

Long-Term Debt and Credit Facilities - Debt Payable within One Year (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Notes and loans payable	$ 8	$ 310
Current portion of long-term debt	652	20
Debt payable within one year	$ 660	$ 330

Long-Term Debt and Credit Fac_5

Long-Term Debt and Credit Facilities - Schedule of Long-Term Debt and Finance Lease Maturities (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 652
2026	1,035
2027	509
2028	612
2029	519
Thereafter	3,678
Total	$ 7,005

Long-Term Debt and Credit Fac_6

Long-Term Debt and Credit Facilities - Narrative (Details) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 31, 2023	Nov. 30, 2022	Dec. 31, 2024
Revolving Credit Facility
Debt Instrument [Line Items]
Unused borrowing capacity			$ 3,725,000,000
Amended Foreign Revolving Credit Facility 3000 Million Capacity
Debt Instrument [Line Items]
Debt instrument term		5 years
Maximum borrowing capacity		$ 3,000,000,000
Ten year notes at 3.250 percent number
Debt Instrument [Line Items]
Face amount			$ 500,000,000
Debt instrument term			10 years
Fixed interest rate			3.25%
Three Year Notes at 4.800 Percent Number
Debt Instrument [Line Items]
Face amount	$ 500,000,000
Debt instrument term	3 years
Fixed interest rate	4.80%
Five Year Notes at 4.600 Percent Number
Debt Instrument [Line Items]
Face amount	$ 500,000,000
Debt instrument term	5 years
Fixed interest rate	4.60%
Ten Year Notes at 4.600 Percent Number
Debt Instrument [Line Items]
Face amount	$ 500,000,000
Debt instrument term	10 years
Fixed interest rate	4.60%

Fair Value Measurements and F_3

Fair Value Measurements and Financial Instruments - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) country	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Minimum number of countries and territories serving consumers (more than) (in countries and territories) | country	200
Total	$ 7,005
Carrying Value
Debt Instrument [Line Items]
Total	7,941	$ 8,239
Fair Value, Inputs, Level 2
Debt Instrument [Line Items]
Estimated fair value of long-term debt	$ 7,433	$ 7,862

Fair Value Measurements and F_4

Fair Value Measurements and Financial Instruments - Fair Value of Derivative Instruments and Other Financial Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Designated derivative instruments
Derivative asset	$ 33	$ 19
Derivative liability	23	26
Other financial instruments
Investments fair value	$ 160	$ 179
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other accruals	Other accruals
Foreign currency contracts
Designated derivative instruments
Derivative asset	$ 33	$ 19
Derivative liability	22	25
Commodity contracts
Designated derivative instruments
Derivative asset	0	0
Derivative liability	1	1
Other current assets
Other financial instruments
Marketable securities	$ 160	$ 179

Fair Value Measurements and F_5

Fair Value Measurements and Financial Instruments - Schedule of Notional Values (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	$ 1,669	$ 1,625
Fair Value Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	1,669	1,625
Fair Value Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Fair Value Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	1,041	908
Cash Flow Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	1,023	869
Cash Flow Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	0	0
Cash Flow Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	18	39
Net Investment Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	4,039	4,188
Net Investment Hedges | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	289	280
Net Investment Hedges | Foreign Currency Debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	3,750	3,908
Net Investment Hedges | Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional value of derivative	$ 0	$ 0

Fair Value Measurements and F_6

Fair Value Measurements and Financial Instruments - Schedule of Gain (Loss) Included in OCI (Details) - Net Investment Hedges - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Net investment hedges [Abstract]
Total gain (loss) on investment hedges	$ 253	$ (158)
Foreign currency contracts
Net investment hedges [Abstract]
Gain (loss) on net investment hedges	42	(34)
Foreign Currency Debt
Net investment hedges [Abstract]
Gain (loss) on net investment hedges	$ 211	$ (124)

Capital Stock and Stock-Based_3

Capital Stock and Stock-Based Compensation Plans - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 USD ($) plan shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 10, 2022 USD ($)
Preference Stock [Abstract]
Shares authorized (in shares) | shares	50,262,150
Stock Repurchases [Abstract]
Repurchased stock	$ 1,739,000,000	$ 1,128,000,000	$ 1,308,000,000
Stock-Based Compensation [Abstract]
Number of stockholder approved plans, current | plan	1
Total stock-based compensation expense charged against pretax income	$ 135,000,000	122,000,000	125,000,000
Total income tax benefit from stock compensation	$ 26,000,000	22,000,000	25,000,000
Additional disclosures pertaining to stock based compensation [Abstract]
Contractual term (in years)	8 years
Vesting period (in years)	3 years
Stock-based compensation, additional disclosures [Abstract]
Tax benefit from exercise of stock options and vesting of restricted stock unit awards	$ 18,000,000	4,000,000	2,000,000
Proceeds from exercise of stock options	$ 638,000,000	380,000,000	418,000,000
Stock Option Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Number of shares available for grant (in shares) | shares	19,248,078
Unrecognized compensation expense	$ 12,000,000
Unrecognized compensation expense, weighted-average period of recognition in years	1 year 3 months 18 days
Stock-based compensation, additional disclosures [Abstract]
Total intrinsic value of options exercised	$ 150,000,000	28,000,000	47,000,000
Performance Shares | Incentive Stock Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Vesting period (in years)	3 years
Unrecognized compensation expense	$ 32,000,000
Time-Vested Stock | Incentive Stock Plans
Additional disclosures pertaining to stock based compensation [Abstract]
Vesting period (in years)	3 years
Number of shares available for grant (in shares) | shares	7,324,623
Unrecognized compensation expense	$ 68,000,000
Unrecognized compensation expense, weighted-average period of recognition in years	1 year 7 months 6 days
Stock-based compensation, additional disclosures [Abstract]
Total fair value of shares vested	$ 72,000,000	$ 45,000,000	$ 40,000,000
Program 2022
Stock Repurchases [Abstract]
Stock repurchase program, authorized amount				$ 5,000,000,000
Repurchased stock	$ 1,739,000,000

Capital Stock and Stock-Based_4

Capital Stock and Stock-Based Compensation Plans - Summary of Common Stock and Treasury Stock Activity (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Common Stock Outstanding
Common stock balance, January 1 (in shares)	821,412,769	830,212,606	840,480,284
Common stock acquired (in shares)	18,321,422	14,735,909	17,060,788
Shares issued for stock options (in shares)	8,606,699	5,318,430	5,654,692
Shares issued for restricted stock and other (in shares)	876,652	617,642	1,138,418
Common stock balance, December 31 (in shares)	812,574,698	821,412,769	830,212,606
Treasury Stock
Treasury stock balance, January 1 (in shares)	644,293,591	635,493,754	625,226,076
Common stock acquired (in shares)	18,321,422	14,735,909	17,060,788
Shares issued for stock options (in shares)	8,606,699	5,318,430	5,654,692
Shares issued for restricted stock and other (in shares)	876,652	617,642	1,138,418
Treasury stock balance, December 31 (in shares)	653,131,662	644,293,591	635,493,754

Capital Stock and Stock-Based_5

Capital Stock and Stock-Based Compensation Plans - Fair Value Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Expected term of options	6 years	6 years	6 years
Expected volatility rate	20.50%	19.80%	21.10%
Risk-free interest rate	3.80%	4.30%	3%
Expected dividend yield	2.10%	2.50%	2.40%
Weighted-average estimated fair value (in dollars per share)	$ 22.65	$ 14.89	$ 14.71

Capital Stock and Stock-Based_6

Capital Stock and Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Options - beginning balance (in shares) | shares	20,742
Granted (in shares) | shares	955
Exercised (in shares) | shares	(8,662)
Forfeited (in shares) | shares	(240)
Expired (in share) | shares	(21)
Options - ending balance (in shares) | shares	12,774
Options exercisable (in shares) | shares	9,265
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options - beginning of period (in dollars per share) | $ / shares	$ 75
Options - shares granted (in dollars per share) | $ / shares	106
Options - shares exercised (in dollars per share) | $ / shares	74
Options - shares forfeited (in dollars per share) | $ / shares	76
Options - shares expired (in dollars per share) | $ / shares	73
Options - end of period (in dollars per share) | $ / shares	78
Options exercisable - end of period (in dollars per share) | $ / shares	$ 76
Weighted average remaining contractual life, options outstanding (in years)	5 years
Weighted average remaining contractual life, options exercisable (in years)	4 years
Intrinsic value of unexercised in-the-money options, options outstanding | $	$ 176
Intrinsic value of unexercised in-the-money options, options exercisable | $	$ 136

Capital Stock and Stock-Based_7

Capital Stock and Stock-Based Compensation Plans - Summary of Performance Restricted Stock Activity (Details) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Shares (in thousands)
Restricted stock awards - beginning balance (in shares) | shares	1,069
Granted (in shares) | shares	321
Vested (in shares) | shares	(283)
Forfeited (in shares) | shares	(89)
Change due to performance and/or market condition achievement (in shares) | shares	19
Restricted stock awards - ending balance (in shares) | shares	1,037
Weighted Average Grant Date Fair Value Per Award
Restricted stock awards - beginning of period (in dollars per share) | $ / shares	$ 68
Restricted stock awards - shares granted (in dollars per share) | $ / shares	91
Restricted stock awards - shares vested (in dollars per share) | $ / shares	70
Restricted stock awards - shares forfeited (in dollars per share) | $ / shares	72
Change due to performance and/or market condition achievement (in dollars per share | $ / shares	57
Restricted stock awards - end of period (in dollars per share) | $ / shares	$ 74

Capital Stock and Stock-Based_8

Capital Stock and Stock-Based Compensation Plans - Summary of Restricted Stock Activity (Details) - Time-Vested Stock shares in Thousands	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Shares (in thousands)
Restricted stock awards - beginning balance (in shares) | shares	2,174
Granted (in shares) | shares	854
Vested (in shares) | shares	(951)
Forfeited (in shares) | shares	(90)
Restricted stock awards - ending balance (in shares) | shares	1,987
Weighted Average Grant Date Fair Value Per Award
Restricted stock awards - beginning of period (in dollars per share) | $ / shares	$ 76
Restricted stock awards - shares granted (in dollars per share) | $ / shares	105
Restricted stock awards - shares vested (in dollars per share) | $ / shares	76
Restricted stock awards - shares forfeited (in dollars per share) | $ / shares	77
Restricted stock awards - end of period (in dollars per share) | $ / shares	$ 88

Employee Stock Ownership Plan (

Employee Stock Ownership Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Shares in ESOP (in shares)	7,428,343	8,348,104
Outstanding borrowings in the ESOP	$ 0
Common shares released and allocated to participant accounts (in shares)	7,334,758
Common shares available for future allocation to participant accounts (in shares)	93,585
Annual ESOP expense	$ 0	$ 0	$ 0
Dividends paid by the Company on shares held by the ESOP	16,000,000	17,000,000	19,000,000
Company contributions to the ESOP	$ 0	$ 0	$ 0

Retirement Plans and Other Re_3

Retirement Plans and Other Retiree Benefits - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
ERISA litigation matter	$ 267		$ 0	$ 267	$ 0
Expected benefit payments from company assets			95
Pension Plans | United States
Defined Benefit Plan Disclosure [Line Items]
ERISA litigation matter		$ 267	0	267	0
Actuarial gain			$ (39)	$ (43)	(46)
Percentage of investments in Company's common stock			0%	0%
U.S. plans assets purchased to Company (in shares)			0	0
Defined benefit plan dividends received on employer securities			$ 0	$ 0
Expected long-term rate of return on plan assets			6.50%
Average annual rates of return for the most recent 1-year period			5%
Average annual rates of return for the most recent 5-year period			2%
Average annual rates of return for the most recent 10-year period			4%
Average annual rates of return for the most recent 15-year period			6%
Average annual rates of return for the most recent 25-year period			5%
Other postretirement charges			$ 5	3	13
Voluntary contributions to postretirement plans			0	0	0
Pension Plans | International
Defined Benefit Plan Disclosure [Line Items]
ERISA litigation matter			0	0	0
Actuarial gain			$ (5)	(5)	(7)
Expected long-term rate of return on plan assets			5.69%
Other postretirement charges			$ 0	2	4
Other Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
ERISA litigation matter			0	0	0
Actuarial gain			$ (4)	(1)	(14)
Medical cost trend rate assumed for next fiscal year			7%
Ultimate medical cost trend rate			4.50%
Year which ultimate medical cost trend rate is reached			2030
Other postretirement charges			$ 0	$ 0	$ 2
Defined Benefit Plan, Health Care Cost Trend Rate Assumed			5%

Retirement Plans and Other Re_4

Retirement Plans and Other Retiree Benefits - Schedule of Target Asset Allocation (Details)	Dec. 31, 2024
United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	100%
International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	100%
Equity securities | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	26%
Equity securities | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	17%
Fixed income securities | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	60%
Fixed income securities | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	63%
Other investments | United States
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	14%
Other investments | International
Defined Benefit Plan, Plan Assets, Allocations [Abstract]
Target asset allocation	20%

Retirement Plans and Other Re_5

Retirement Plans and Other Retiree Benefits - Allocation of Plan Assets and Level of Valuation Input, by Major Asset Category (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Percent of fixed income assets invested in US treasury or agency securities		30%
Minimum
Defined Benefit Plan Disclosure [Line Items]
Investment redemption notice period	0 months
Maximum
Defined Benefit Plan Disclosure [Line Items]
Investment redemption notice period	3 months
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,295	$ 1,360	$ 1,363
United States | Pension Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	886	936
United States | Pension Plans | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	448	454
United States | Pension Plans | Cash and cash equivalents | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	226	206
United States | Pension Plans | U.S. common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	0
United States | Pension Plans | International common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Pooled funds | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35	20
United States | Pension Plans | Fixed income securities | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	624	710
United States | Pension Plans | Guaranteed investment contracts | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Domestic, developed and emerging markets equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	223	315
United States | Pension Plans | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	68	99
United States | Pension Plans | Hedge funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Multi-Asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	157	40
United States | Pension Plans | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
United States | Pension Plans | Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(39)	(30)
International | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	537	566	$ 516
International | Pension Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	246	254
International | Pension Plans | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	286	312
International | Pension Plans | Cash and cash equivalents | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	21	14
International | Pension Plans | U.S. common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	2
International | Pension Plans | International common stocks | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15	20
International | Pension Plans | Pooled funds | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	103	113
International | Pension Plans | Fixed income securities | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	75	71
International | Pension Plans | Guaranteed investment contracts | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	34
International | Pension Plans | Domestic, developed and emerging markets equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	55
International | Pension Plans | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	222	219
International | Pension Plans | Hedge funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	7
International | Pension Plans | Multi-Asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	1
International | Pension Plans | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	27	30
International | Pension Plans | Other assets and liabilities, net
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 5	$ 0

Retirement Plans and Other Re_6

Retirement Plans and Other Retiree Benefits - Summary of Defined Benefit and Other Retiree Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amounts Recognized in Balance Sheet
Current liabilities	$ (93)	$ (96)
Pension Plans
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Accumulated benefit obligation	2,075	2,204
Other Retiree Benefit Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	665	658
Service cost	7	7	$ 18
Interest cost	36	38	36
Participants’ contributions	0	0
Plan amendments	0	(33)
Actuarial loss (gain)	(14)	38
Foreign exchange impact	(8)	4
Termination benefits	0	0
Curtailments and settlements	0	0
Benefit payments	(54)	(47)
ERISA litigation matter	0	0
Benefit obligations at end of year	632	665	658
Change in Plan Assets
Fair value of plan assets at beginning of year	0	0
Actual return on plan assets	0	0
Company contributions	54	47
Participants’ contributions	0	0
Foreign exchange impact	0	0
Settlements and acquisitions	0	0
Benefit payments	(54)	(47)
Fair value of plan assets at end of year	0	0	0
Funded Status
Benefit obligations at end of year	632	665	658
Fair value of plan assets at end of year	0	0	0
Net amount recognized	(632)	(665)
Amounts Recognized in Balance Sheet
Noncurrent assets	0	0
Current liabilities	(51)	(53)
Noncurrent liabilities	(581)	(612)
Net amount recognized	(632)	(665)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	109	128
Transition/prior service cost(credit)	(159)	(180)
Amounts recognized in accumulated other comprehensive income	(50)	(52)
Accumulated benefit obligation	632	665
Accumulated benefit obligation	$ 0	$ 0
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	5.74%	5.37%
Long-term rate of compensation increase	0%	0%
ESOP growth rate	6%	6%
Medical cost trend rate of increase	7%	6%
Interest Crediting Rate	0%	0%
United States | Pension Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	$ 1,922	$ 1,673
Service cost	1	0	0
Interest cost	99	91	64
Participants’ contributions	0	0
Plan amendments	0	0
Actuarial loss (gain)	(54)	36
Foreign exchange impact	0	0
Termination benefits	5	3
Curtailments and settlements	(1)	0
Benefit payments	(141)	(148)
ERISA litigation matter	0	267
Benefit obligations at end of year	1,831	1,922	1,673
Change in Plan Assets
Fair value of plan assets at beginning of year	1,360	1,363
Actual return on plan assets	49	115
Company contributions	29	30
Participants’ contributions	0	0
Foreign exchange impact	0	0
Settlements and acquisitions	(2)	0
Benefit payments	(141)	(148)
Fair value of plan assets at end of year	1,295	1,360	1,363
Funded Status
Benefit obligations at end of year	1,831	1,922	1,673
Fair value of plan assets at end of year	1,295	1,360	1,363
Net amount recognized	(536)	(562)
Amounts Recognized in Balance Sheet
Noncurrent assets	1	1
Current liabilities	(27)	(28)
Noncurrent liabilities	(510)	(535)
Net amount recognized	(536)	(562)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	710	767
Transition/prior service cost(credit)	0	0
Amounts recognized in accumulated other comprehensive income	710	767
Accumulated benefit obligation	$ 1,818	$ 1,907
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	5.73%	5.40%
Expected long-term rate of return on plan assets	6.50%
Long-term rate of compensation increase	3.50%	3.50%
ESOP growth rate	0%	0%
Medical cost trend rate of increase	0%	0%
Interest Crediting Rate	5.58%	4.99%
International | Pension Plans
Change in Benefit Obligations
Benefit obligations at beginning of year	$ 776	$ 675
Service cost	16	15	15
Interest cost	33	33	21
Participants’ contributions	5	5
Plan amendments	0	0
Actuarial loss (gain)	(11)	65
Foreign exchange impact	(40)	29
Termination benefits	0	2
Curtailments and settlements	(18)	(6)
Benefit payments	(41)	(42)
ERISA litigation matter	0	0
Benefit obligations at end of year	720	776	675
Change in Plan Assets
Fair value of plan assets at beginning of year	566	516
Actual return on plan assets	18	26
Company contributions	37	39
Participants’ contributions	5	5
Foreign exchange impact	(31)	27
Settlements and acquisitions	(17)	(5)
Benefit payments	(41)	(42)
Fair value of plan assets at end of year	537	566	516
Funded Status
Benefit obligations at end of year	720	776	675
Fair value of plan assets at end of year	537	566	$ 516
Net amount recognized	(183)	(210)
Amounts Recognized in Balance Sheet
Noncurrent assets	47	48
Current liabilities	(15)	(15)
Noncurrent liabilities	(215)	(243)
Net amount recognized	(183)	(210)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss)
Actuarial loss	174	177
Transition/prior service cost(credit)	8	9
Amounts recognized in accumulated other comprehensive income	182	186
Accumulated benefit obligation	$ 668	$ 719
Weighted-Average Assumptions Used to Determine Benefit Obligations
Discount rate	4.69%	4.35%
Expected long-term rate of return on plan assets	5.69%
Long-term rate of compensation increase	3.36%	3.19%
ESOP growth rate	0%	0%
Medical cost trend rate of increase	0%	0%
Interest Crediting Rate	3.23%	1.13%

Retirement Plans and Other Re_7

Retirement Plans and Other Retiree Benefits - Benefit Obligation Exceeds Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 2,251	$ 2,352
Fair value of plan assets	1,486	1,532
Accumulated benefit obligation	2,075	2,204
Fair value of plan assets	1,345	1,428
Other Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	0	0
Fair value of plan assets	$ 0	$ 0

Retirement Plans and Other Re_8

Retirement Plans and Other Retiree Benefits - Summary of Other Retiree Benefit Plans (Details) - Other Retiree Benefit Plans - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 632	$ 665
Fair value of plan assets	$ 0	$ 0

Retirement Plans and Other Re_9

Retirement Plans and Other Retiree Benefits - Summary of Net Periodic Benefit Costs (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Components of Net Periodic Benefit Cost
ERISA litigation matter	$ 267		$ 0	$ 267	$ 0
Other Retiree Benefit Plans
Components of Net Periodic Benefit Cost
Service cost			7	7	18
Interest cost			36	38	36
Expected return on plan assets			0	0	0
Amortization of transition and prior service costs (credits)			(21)	(20)	(6)
Amortization of actuarial loss			4	1	14
Net periodic benefit cost			26	26	62
Other postretirement charges			0	0	2
ERISA litigation matter			0	0	0
Total pension cost			$ 26	$ 26	$ 64
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate			5.37%	5.67%	3.06%
Long-term rate of compensation increase			0%	0%	0%
ESOP growth rate			6%	6%	6%
Medical cost trend rate of increase			6%	6.25%	6%
Interest Crediting Rate			0%	0%	0%
United States | Pension Plans
Components of Net Periodic Benefit Cost
Service cost			$ 1	$ 0	$ 0
Interest cost			99	91	64
Expected return on plan assets			(85)	(79)	(101)
Amortization of transition and prior service costs (credits)			0	0	0
Amortization of actuarial loss			39	43	46
Net periodic benefit cost			54	55	9
Other postretirement charges			5	3	13
ERISA litigation matter		$ 267	0	267	0
Total pension cost			$ 59	$ 325	$ 22
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate			5.40%	5.66%	2.98%
Expected long-term rate of return on plan assets			6.50%	6.25%	5.70%
Long-term rate of compensation increase			3.50%	3.50%	3.50%
ESOP growth rate			0%	0%	0%
Medical cost trend rate of increase			0%	0%	0%
Interest Crediting Rate			4.99%	5.21%	2.82%
International | Pension Plans
Components of Net Periodic Benefit Cost
Service cost			$ 16	$ 15	$ 15
Interest cost			33	33	21
Expected return on plan assets			(29)	(25)	(21)
Amortization of transition and prior service costs (credits)			1	1	1
Amortization of actuarial loss			5	5	7
Net periodic benefit cost			26	29	23
Other postretirement charges			0	2	4
ERISA litigation matter			0	0	0
Total pension cost			$ 26	$ 31	$ 27
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost
Discount rate			4.61%	4.75%	2.10%
Expected long-term rate of return on plan assets			5.69%	4.66%	2.72%
Long-term rate of compensation increase			3.24%	3.22%	2.89%
ESOP growth rate			0%	0%	0%
Medical cost trend rate of increase			0%	0%	0%
Interest Crediting Rate			0.64%	2.28%	0.84%

Retirement Plans and Other R_10

Retirement Plans and Other Retiree Benefits - Expected Contributions and Benefit Payments (Details) $ in Millions	Dec. 31, 2024 USD ($)
Total benefit payments [Abstract]
2025	$ 471
2026	238
2027	241
2028	242
2029	242
2030-2034	1,174
Other Retiree Benefit Plans
Total benefit payments [Abstract]
2025	52
2026	54
2027	55
2028	55
2029	55
2030-2034	274
United States | Pension Plans
Total benefit payments [Abstract]
2025	377
2026	143
2027	143
2028	142
2029	141
2030-2034	653
International | Pension Plans
Total benefit payments [Abstract]
2025	42
2026	41
2027	43
2028	45
2029	46
2030-2034	$ 247

Income Taxes - Components of In

Income Taxes - Components of Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
United States	$ 1,084	$ 692	$ 1,169
International	2,872	2,700	1,491
Income before income taxes	$ 3,956	$ 3,392	$ 2,660

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
United States	$ 188	$ 72	$ 199
International	719	865	494
Total Provision for income taxes	$ 907	$ 937	$ 693

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Goodwill and intangible assets	$ 3	$ 1	$ 106
Property, plant and equipment	12	(13)	2
Pension and other retiree benefits	(6)	68	(1)
Stock-based compensation	(14)	2	(3)
Right-of-use assets/lease liabilities	2	1	(5)
Tax credits and tax loss carryforwards, net of valuation allowance	37	29	8
Deferred withholding tax	(14)	7	8
Research and Experimentation Capitalization	21	29	58
Other, net	(8)	11	(10)
Total deferred tax benefit (provision)	$ 33	$ 135	$ 163

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Tax at United States statutory rate	21%	21%	21%
State income taxes, net of federal benefit	0.50%	(0.10%)	0.80%
Earnings taxed at other than United States statutory rate	4.10%	5.40%	5.40%
Non-deductible goodwill impairment charges	0%	0%	1.90%
Foreign-derived intangible income benefit	(2.60%)	(2.40%)	(2.60%)
Foreign tax matter	0%	3.70%	0%
Other, net	(0.10%)	0%	(0.40%)
Effective tax rate	22.90%	27.60%	26.10%

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred tax liabilities:
Goodwill and intangible assets	$ (389)	$ (412)
Property, plant and equipment	(397)	(420)
Right-of-use assets	(126)	(126)
Deferred withholding tax	(110)	(96)
Other	(130)	(34)
Total deferred tax liabilities	(1,152)	(1,088)
Deferred tax assets:
Pension and other retiree benefits	272	295
Tax credits and tax loss carryforwards	430	356
Lease liabilities	137	134
Accrued liabilities	223	221
Stock-based compensation	61	75
Research and Experimentation Capitalization	108	87
Other	101	60
Total deferred tax assets	1,332	1,228
Valuation Allowance	(328)	(287)	$ (129)	$ (120)
Net deferred tax assets	1,004	941
Net deferred income taxes	$ (148)	$ (147)

Income Taxes - Change in Valuat

Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Balance, January 1	$ 287	$ 129	$ 120
Balance, December 31	328	287	129
Charged to costs and expenses
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Valuation allowance, deferred tax asset, additions (deductions)	56	158	14
Deductions
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Valuation allowance, deferred tax asset, additions (deductions)	$ (15)	$ 0	$ (5)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 15, 2022 memberState
Income Tax Disclosure [Abstract]
Net operating loss and capital loss carryforwards		$ 37
Net operating loss and capital loss carryforwards, set to begin expiring		6
Net operating loss carryforwards, not subject to expiration		13
Net operating loss carryforward, valuation allowance		18
Tax credit carryforward		393
Tax credit carryforward, subject to expiration		66
Tax credit carryforward, not subject to expiration		17
tax credit carryforward, valuation allowance		310
Income tax expense (benefit) allocated directly to equity		55	$ (19)	$ 164
Unrecognized tax benefits that would impact effective tax rate		286
Interest (income) expense recognized related to unrecognized tax benefits		22	10	8
Accrued interest related to unrecognized tax benefits		68	45	40
Cumulative effect of change in tax position	$ 148
Withholding tax reserves, prior year reversals	$ 22	53	$ 61	$ 21
Number of member states of the European Union | memberState					27
Tax plus interest for years 2010 through 2018		$ 153

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized tax benefits:
Balance, January 1		$ 314	$ 298	$ 245
Increases as a result of tax positions taken during the current year		37	73	32
Decreases of tax positions taken during prior years	$ (22)	(53)	(61)	(21)
Increases of tax positions taken during prior years		10	6	46
Decreases as a result of settlements with taxing authorities and the expiration of statutes of limitations		(3)	(2)	(2)
Effect of foreign currency rate movements		(9)	0	(2)
Balance, December 31		$ 296	$ 314	$ 298

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net income attributable to Colgate-Palmolive Company
Basic EPS	$ 2,889	$ 2,300	$ 1,785
Diluted EPS	$ 2,889	$ 2,300	$ 1,785
Shares (millions)
Basic EPS (in shares)	819.1	827.4	836.4
Stock options and restricted stock units (in shares)	4.1	1.8	2.4
Diluted EPS (in shares)	823.2	829.2	838.8
Per Share
Basic EPS (in dollars per share)	$ 3.53	$ 2.78	$ 2.13
Diluted EPS (in dollars per share)	$ 3.51	$ 2.77	$ 2.13

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	295,968	13,719,286	5,236,371
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	100,191	1,183	155,118

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Aug. 31, 2024 petition	Nov. 30, 2023 petition	Mar. 31, 2024 USD ($) case	Dec. 31, 2024 USD ($) case countryAndTerritory	Dec. 31, 2023 USD ($) case	Dec. 31, 2022 USD ($)	Dec. 31, 2005 USD ($)
Loss Contingencies [Line Items]
Contractual commitments, amount | $				$ 568
Number of countries in which entity operates (more than) | countryAndTerritory				200
Brazilian internal revenue authority, matter 1 | $				$ 93
Loss contingency, pending claims, number (in cases)				3
Loss contingency, number of cases on appeal				2
Loss contingency, petitions for removal of penalty portion of claim | petition		3
Loss contingency, petitions approved for removal of penalty portion of claim | petition	2
Brazilian internal revenue authority, matter 2 | $							$ 47
Loss contingency, pending claims, number (in cases)				309	279
Loss contingency, new claims filed, number (in cases)				142
Loss contingency, claims dismissed or settled, number (in cases)				111
Loss contingency, cases removed from case count				1
Loss contingency, number of cases resulting in verdict for the Company			1
ERISA litigation matter | $			$ 267	$ 0	$ 267	$ 0
Minimum
Loss Contingencies [Line Items]
Range of reasonably possible losses | $				0
Maximum
Loss Contingencies [Line Items]
Range of reasonably possible losses | $				$ 250

Segment Information - Narrative

Segment Information - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments (in segments) | segment	2
Number of geographically reportable operating segments (in segments) | segment	5
Restructuring costs	$ 59	$ 24	$ 90
Restructuring and related cost, incurred cost	$ 20	1
Goodwill and intangible assets impairment charges			721
Gain on sale of land			47
Corporate
Segment Reporting Information [Line Items]
Acquisition-related costs			$ 19
Global Growth and Efficiency Program
Segment Reporting Information [Line Items]
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Operating Income (Loss)		Operating Income (Loss)
Restructuring and related cost, incurred cost		27
Global Productivity Initiative
Segment Reporting Information [Line Items]
Restructuring and related cost, incurred cost	$ 85	32	$ 95
Operating Profit | Global Growth and Efficiency Program
Segment Reporting Information [Line Items]
Restructuring and related cost, incurred cost		$ 25
Operating Profit | Global Productivity Initiative | Corporate
Segment Reporting Information [Line Items]
Restructuring costs	$ 85
Sales Revenue, Net
Segment Reporting Information [Line Items]
Percentage of consolidated Net sales represented by sales outside US	66.70%
Percentage of consolidated Net sales coming from emerging markets	45%
Sales Revenue, Net | Customer Concentration Risk | Walmart, Inc.
Segment Reporting Information [Line Items]
Percentage of consolidated sales represented by one customer	11%

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net sales	$ 20,101	$ 19,457	$ 17,967
Cost of sales	7,940	8,131	7,719
Selling, general and administrative expenses	7,729	7,151	6,565
Operating profit	4,268	3,984	2,893
Capital expenditures	561	705	696
Depreciation and amortization	605	567	545
Total long lived assets	4,951	5,073
United States
Segment Reporting Information [Line Items]
Total long lived assets	2,728	2,733
Non-US
Segment Reporting Information [Line Items]
Total long lived assets	2,223	2,340
Total Oral, Personal and Home Care | United States
Segment Reporting Information [Line Items]
Net sales	3,640	3,625	3,511
Pet Nutrition | United States
Segment Reporting Information [Line Items]
Net sales	3,059	2,918	2,432
Operating Segments | Total Oral, Personal and Home Care
Segment Reporting Information [Line Items]
Net sales	15,618	15,167	14,254
Operating profit	4,088	3,882	3,348
Capital expenditures	317	311	308
Depreciation and amortization	378	372	387
Operating Segments | Total Oral, Personal and Home Care | North America
Segment Reporting Information [Line Items]
Net sales	4,113	4,091	4,002
Cost of sales	1,571	1,588	1,649
Selling, general and administrative expenses	1,668	1,594	1,567
Other	36	37	46
Operating profit	839	871	741
Capital expenditures	52	46	66
Depreciation and amortization	124	116	128
Operating Segments | Total Oral, Personal and Home Care | Latin America
Segment Reporting Information [Line Items]
Net sales	4,782	4,640	3,982
Cost of sales	1,933	1,977	1,885
Selling, general and administrative expenses	1,328	1,241	1,059
Other	(5)	5	(71)
Operating profit	1,526	1,417	1,108
Capital expenditures	126	146	121
Depreciation and amortization	100	98	93
Operating Segments | Total Oral, Personal and Home Care | Europe
Segment Reporting Information [Line Items]
Net sales	2,770	2,571	2,362
Cost of sales	1,050	1,069	1,023
Selling, general and administrative expenses	1,031	899	778
Other	31	31	28
Operating profit	658	573	534
Capital expenditures	63	44	31
Depreciation and amortization	65	65	68
Operating Segments | Total Oral, Personal and Home Care | Asia Pacific
Segment Reporting Information [Line Items]
Net sales	2,858	2,782	2,826
Cost of sales	1,078	1,108	1,160
Selling, general and administrative expenses	997	925	954
Other	(30)	(18)	(24)
Operating profit	812	767	737
Capital expenditures	64	65	60
Depreciation and amortization	81	84	89
Operating Segments | Total Oral, Personal and Home Care | Africa/Eurasia
Segment Reporting Information [Line Items]
Net sales	1,095	1,083	1,082
Cost of sales	432	442	447
Selling, general and administrative expenses	395	377	389
Other	16	9	18
Operating profit	253	254	228
Capital expenditures	12	10	30
Depreciation and amortization	8	9	9
Operating Segments | Pet Nutrition
Segment Reporting Information [Line Items]
Net sales	4,483	4,290	3,713
Cost of sales	1,869	1,964	1,569
Selling, general and administrative expenses	1,641	1,493	1,287
Other	8	26	7
Operating profit	965	806	850
Capital expenditures	143	301	297
Depreciation and amortization	132	101	65
Corporate
Segment Reporting Information [Line Items]
Operating profit	(784)	(704)	(1,305)
Capital expenditures	101	93	91
Depreciation and amortization	$ 95	$ 94	$ 93

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) leaseRenewalOption	Dec. 31, 2023 USD ($)
Leases [Abstract]
Number of lease renewal options (one or more) | leaseRenewalOption	1
Operating lease, payments	$ 132	$ 171
Right-of-use asset obtained in exchange for operating lease liability	$ 141	$ 139
Operating lease, weighted average remaining lease term	7 years	8 years
Operating lease, weighted average discount rate	4.40%	4.50%

Leases - Balance Sheet (Details

Leases - Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Other assets	$ 529	$ 491
Other accruals	107	95
Other liabilities	456	420
Total operating lease liabilities	$ 563	$ 515
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other accruals	Other accruals
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other liabilities	Other liabilities

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Commitments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2025	$ 126
2026	108
2027	101
2028	80
2029	58
Thereafter	182
Total lease commitments	655
Less: Interest	(92)
Present value of lease liabilities	$ 563	$ 515

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease cost	$ 144	$ 136
Short-term lease cost	3	3
Variable lease cost	19	20
Sublease Income	(2)	(2)
Total lease cost	$ 164	$ 157

Supplemental Income Statement_3

Supplemental Income Statement Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other (income) expense, net
Amortization of intangible assets	$ 75	$ 72	$ 80
Equity income	(22)	(17)	(12)
2022 Global Productivity Initiative	59	24	90
Product recall costs	0	25	0
Losses (gains) from marketable securities and other assets	6	11	(22)
Indirect tax payments (refunds)	27	18	(14)
Gain on the sale of land in Asia Pacific	0	0	(47)
Acquisition-related costs	0	0	19
Other, net	19	58	(25)
Total Other (income) expense, net	164	191	69
Research and development	355	343	320
Advertising	$ 2,720	$ 2,371	$ 1,997

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Inventories by Major Class (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Inventories
Raw materials and supplies	$ 631	$ 606
Work-in-process	46	46
Finished goods	1,431	1,411
Total Inventories, net	2,108	2,063
Non-current inventory, net	(121)	(129)
Current Inventories, net	$ 1,987	$ 1,934

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Inventories valued under LIFO	$ 453	$ 471
Excess of current cost over LIFO cost	$ 105	$ 120

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, plant and equipment, net
Land	$ 226	$ 227
Buildings	2,056	2,047
Manufacturing machinery and equipment	6,265	6,365
Other equipment	1,580	1,647
Property, plant and equipment, gross	10,127	10,286
Accumulated depreciation	(5,705)	(5,704)
Property, plant and equipment, net	$ 4,422	$ 4,582

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Schedule of Other Current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Other current assets
Marketable securities	$ 160	$ 179
Prepaids	520	595
Derivatives	33	19
Total Other current assets	$ 713	$ 793

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information - Schedule of Other Accruals (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Other accruals
Accrued advertising and consumer and trade promotions	$ 912	$ 882
Accrued payroll and employee benefits	437	403
Accrued taxes other than income taxes	162	167
Restructuring accrual	15	11
Pension and other retiree benefits	93	96
Lease liabilities due in one year	107	95
Accrued interest	72	78
Derivatives	23	26
Dividend payable	408	0
Other	662	619
Other accruals	$ 2,891	$ 2,377

Supplemental Balance Sheet In_8

Supplemental Balance Sheet Information - Schedule of Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Other liabilities
Pension and other retiree benefits	$ 1,306	$ 1,390
Long-term lease liabilities	456	420
Restructuring accrual	29	0
Other	320	305
Total Other liabilities	$ 2,111	$ 2,115

Supplemental Other Comprehens_3

Supplemental Other Comprehensive Income (Loss) Information - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), net of tax	$ (292)	$ 75	$ 327
Accumulated Other Comprehensive Income (Loss)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), net of tax	(284)	117	331
Cumulative translation adjustments, pre-tax
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), pretax	(298)	127	(113)
Tax amounts	(37)	13	(29)
Other comprehensive income (loss), net of tax	(335)	140	(142)
Retirement Plan and other retiree benefit adjustments, pre-tax
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), before reclassifications, pretax	31	(49)	466
Reclassification from AOCI, pretax	28	30	62
Other comprehensive income (loss), pretax	59	(19)	528
Tax amounts	(16)	3	(115)
Other comprehensive income (loss), net of tax	43	(16)	413
Gains (losses) on cash flow hedges, pre-tax
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other comprehensive income (loss), pretax	10	(10)	80
Tax amounts	(2)	3	(20)
Other comprehensive income (loss), net of tax	$ 8	$ (7)	$ 60

Supplemental Other Comprehens_4

Supplemental Other Comprehensive Income (Loss) Information - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Unrecognized pension and other retiree benefit costs, aftertax	$ 605	$ 647
Foreign currency translation losses	$ 3,687	$ 3,351